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Background:  Scientific advancements in oncology allow routine patient cancer genomic 
profiling, which may guide the choice of novel therapies to match genomic alterations for the 
treatment of cancer.  Potential differences in cancer therapy-related symptom severity and 
occurrence as well as health-related quality of life (HRQOL) between patients who receive 
matched therapy and those who do not have not been previously explored.  
Purposes:  The purpose of this study was to describe the characteristics of patients with breast or 
gynecologic cancer who were receiving matched therapy or not matched therapy, as well as to 
describe their cancer therapy-related symptom occurrence and severity, and overall HRQOL.   
Methods: Existing data from the records of 129 patients receiving care at a cancer center in the 
upper Midwest were used for this descriptive correlational research study.  Descriptive statistics 
and multiple linear regression analyses were performed to address the study purpose and aims. 
Results: This study found that patients receiving matched therapy had lower mean therapy-
related symptom checklist (TRSC) scores (M = 14.7) than patients receiving not matched therapy 
(M = 16.1).  Compared to prior studies, a higher percentage of patients (29%) added symptoms 
to the TRSC.  TRSC scores for individual symptoms were similar across groups, except pain, 
which was higher in patients receiving matched therapy, and hair loss, which was higher in 
patients receiving not matched therapy.  Patients receiving matched therapy had higher mean 
Health-Related Quality of Life – Linear Analogue Self Assessment (HRQOL-LASA) scores (M 
= 48.1), than patients receiving not matched therapy (M = 45.4).  Patients who had prior therapy 
less than three months prior to the onset of the current therapy had significantly higher TRSC 
total scores than patients with no prior therapy (B = 6.2, p = 0.045). Patients who had a higher 
number of prior lines of therapy had significantly higher HRQOL-LASA scores (B = 0.56, p = 
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0.05).  Patients with higher TRSC scores had significantly lower HRQOL-LASA (B = -0.36, p < 
0.001).        
Conclusions:  Patients receiving matched therapy did not have worse therapy-related symptoms 
or HRQOL.  Findings provide initial information about the symptom experience and HRQOL for 
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 Approximately 14.5 million Americans are either living with cancer or have a history of 
cancer (American Cancer Society [ACS], 2015a).  Breast and gynecologic cancers comprise 
approximately 323,000 of new cancer cases annually, and nearly 71,000 women died from these 
diseases in 2015.  Advancements in cancer screening and treatment have increased the five-year 
survival rate for breast cancer to 89%, and the five-year survival rate for the combined 
gynecologic cancers to 65% (ACS, 2015a).  A significant proportion of women will live more 
than five years after diagnosis without being cured of their disease.  These women will need to 
receive treatment for their cancer for years; consequently their cancer is now considered a 
chronic disease.  Physical and emotional symptoms are experienced throughout the cancer 
continuum, which can negatively interfere with quality of life (QOL) (de Moor et al., 2013; 
Heinze, 2012).  In addition to the personal burden, the treatment of cancer is costly.  Direct 
medical costs for treating breast and gynecologic cancers were an estimated $27.5 billion in 2010 
(Yabroff, Lund, Kepka, & Mariotto, 2011).  Thus, cancer is a major women’s health concern that 
requires further examination and research.  
 The treatment of breast and gynecologic cancers involves different modalities including 
surgery, chemotherapy, and radiation therapy.  Each treatment modality can cause specific side 
effects yet significant overlap exists.  Common side effects arising from these treatment 
modalities include bone marrow suppression, mucositis, diarrhea, nausea/vomiting, and 
neuropathies, thereby contributing to the development of symptoms like fatigue, pain, 
depression, and weakness (DeVita, Lawrence, & Rosenberg, 2011; Reeve et al., 2014; Williams, 
Williams, Ducey, Sears & Tobin, 1997; Williams et al., 2001).  The symptoms experienced 
(symptom experience) differs among individuals, although prior studies suggest the occurrence 
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and severity of the most commonly manifested symptoms varies little across primary cancer 
types (Kirkova et al., 2011; Reeve et al., 2014).  Symptoms arising from the treatment of cancer 
can cause suffering (Cleeland, 2000; Komurcu et al., 2000) and distress (Kirkova, et al., 2010), 
and are determinants of decreased QOL (Janz et al., 2007; Miaskowski et al., 2006; Williams et 
al., 1997; Williams et al., 2001).  Appropriate symptom management is essential for cancer 
patients, which not only can lead to enhanced QOL, but may also lead to greater adherence to 
their cancer treatment and thus improved efficacy. 
 State-of-the-art cancer care now includes personalizing strategies to treat an individual’s 
cancer based on their unique genomic signature, which is found by cancer genomic profile 
testing (commonly abbreviated “genomic profiling”).  Cancer treatment (therapy) that is chosen 
based on the alterations found in genomic profiling is called “matched therapy”.  Matched 
therapy is a shift to a more personalized approach to treating cancer based on the crucial insights 
into the genomic alterations and molecular pathways influencing the development and 
progression of cancer (McDermot, Downing, & Stratton, 2011).  Drugs have been developed that 
block the growth and spread of cancer by interfering with the spread of molecular, or molecular 
targets, involved in the growth and spread of cancer (NCI, 2014).  The use of these drugs is 
called targeted therapy.  Targeted therapies are often combined with other treatment modalities 
such as chemotherapy.  Increasingly, genomic profiling is being incorporated into routine clinical 
practice to identify specific genomic alterations of an individual’s cancer so that the therapies 
selected are more precise.  
 An important issue that must be considered with matched therapy is the tolerability or 
risk/benefit ratio of the matched therapies especially since it involves combining drugs, based on 
an individual’s unique genomic signature, each of which have a narrow margin between efficacy 
and excess toxicity.  Prior studies examining symptoms related to the treatment of cancer and 
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their impact on QOL have focused on not matched therapies (e.g. chemotherapy, radiation, 
surgery).  Matched therapy brings the promise of increased efficacy, but little is known about the 
symptom experience or QOL for patients undergoing this new treatment modality.  
A study to examine patient reported symptom occurrence and severity and health-related 
quality of life (HRQOL) while receiving matched therapy is considered to be a timely and 
valuable endeavor given the current gaps in knowledge about this increasingly utilized approach 
for treating cancer.  Knowledge gained from this study will better prepare health care 
professionals to provide safe, effective, and efficient care to oncology patients.  Such inquiries 
are important to advancing nursing science, because the data from these studies will assist in the 
promotion of health, optimize patient outcomes, and keep nursing at the forefront of science 
(National Institute of Nursing Research [NINR], 2016).  
Background 
 Breast cancer is the most common cancer diagnosis in American women, and remains the 
second leading cause of cancer-related death among American women despite impressive 
advances in screening, detection, and treatment (ACS, 2015a).  Breast cancer is a complex and 
heterogeneous disease with individual biological features and corresponding behaviors (Weigelt 
& Reis-Fiho, 2009; Winer et al., 2009).  Breast cancer is typically classified both by its 
histologic type (tissue in which the cancer originates and its structural pattern) and its molecular 
type (underlying genetic changes).  The majority of breast cancers by histologic type are invasive 
ductal carcinoma (50-80%) followed by invasive lobular carcinoma (5-15%) (Weigelt & Reis-
Fiho, 2009).  Molecular types of breast cancer include luminal (either A or B), human epidermal 
growth factor receptor 2 (HER2), and basal subtypes (Schnitt, 2015).  Luminal subtypes have a 
higher expression of estrogen/progesterone receptors (ER/PR) (luminal A > luminal B) and 
comprise approximately 70% of all invasive breast cancers.  Tumors that exhibit ER and/or PR 
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positivity use estrogen and/or progesterone to promote cancerous cell growth (Kos & Dabbs, 
2016).     
 Representing 15% to 20% of all invasive breast cancer types is the HER2 subtype 
(Biooncology, 2015; Kos & Dabbs, 2016).  This subtype has a higher expression of HER2 and 
has been linked with poorer outcomes (Kos & Dabbs, 2016).  HER2 is a gene that makes HER2 
proteins, which are expressed on a number of body cells (Carpenter & Lo, 2013).  HER2 is a 
member of the human epidermal growth factor receptors (HER) family, (HER1, HER2, HER3, 
HER4) all of which help regulate cell growth, survival, differentiation, and migration through 
several cell signaling pathways (Kos & Dabbs, 2016).  Amplification or overexpression of the 
HER2 gene leads to aggressive and unrestrained neoplastic cell growth and survival (Bose et al., 
2006; Wieduwilt & Moasser, 2008).    
 Basal subtypes have a high expression of basal epithelial genes, and tend to be triple 
negative, meaning the tumor lacks estrogen and progesterone receptors, and is HER2 negative.  
About 15% of invasive breast cancers are classified as basal subtypes and, like the HER2 
subtype, are associated with aggressive tumors and correspondingly poorer prognoses (Schnitt, 
2015).  
 The risk for developing any of the subtypes of invasive ductal carcinoma of the breast is 
dramatically increased by inherited genetic alterations, called germline alterations.  A germline 
alteration refers to the presence of an altered gene within the germ cell, so that the altered gene 
can be passed on to future generations (Genetics Home Reference, 2016).  The most well studied 
germline alterations are the breast cancer susceptibility gene 1 and 2 (BRCA1 and BRCA2) 
(ACS, 2015a).  BRCA1 and BRCA2 produce tumor suppressor proteins, which are involved in 
repairing double strand breaks by homologous recombination (Chandramouly, Willis, & Scully, 
2011; NCI, 2015a).  BRCA1 is the first gene to function in homologous repair, and recruits 
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BRCA2 to the break site.  Loss of function of either gene initiates genomic instability, thereby 
triggering tumor formation (Chandramouly et al., 2011).  By the time a woman reaches 70 years 
of age, 55%-65% of women who inherit a BRCA1 alteration will develop breast cancer while 
around 45% of women who inherit a BRCA2 alteration will develop breast cancer (NCI, 2015a).  
BRCA1 alterations are associated with the basal subtype of breast cancer, while BRCA2 
alterations are generally associated with the luminal B subtype, although this is not universal 
(Larsen et al., 2013).  Five to 10% of all breast cancer cases occur due to germline alterations 
(ACS, 2015a); therefore somatic alterations represent the vast majority of breast cancer causes. 
Somatic alterations are alterations in DNA that are acquired after conception and can occur in 
any cell in the body except germ cells (sperm and egg), meaning they are not passed on to future 
generations (Genetics Home Reference, 2015). 
 Gynecologic cancers, which affect a woman’s reproductive organs, include ovarian, 
fallopian, peritoneal, endometrial, vaginal, vulvar, and cervical cancer.  Endometrial cancer is the 
most common gynecologic cancer, with an estimated 54,870 new cases estimated in 2015, and 
10,170 deaths attributed to this disease (ACS, 2015a).  Ovarian cancer is the seventh most 
common cancer in women with 21,290 new cases estimated in 2015 (ACS, 2015a).  It should be 
noted that cancers of the ovary, fallopian tube, and peritoneal are often combined due to the 
similar clinical and molecular characteristics (Fadare & Khabele, 2015).  Typically fatal, these 
cancers are estimated to be responsible for 14,180 deaths in 2015 (ACS, 2015a).  Approximately 
10-20% of ovarian cancers are linked to a germline alteration such as BRCA1 or BRCA2 
(Fadare & Khabele, 2015).  Roughly 39% of women who inherit the BRCA1 alteration and 17% 
of women who inherit the BRCA2 alteration will develop ovarian cancer by the time they reach 
70 years of age (NCI, 2015a).  The estimated number of deaths for cervical, vulvar, and vaginal 
cancers in 2015 was 4,100 (ACS, 2015a), 1,080 (National Cancer Institute [NCI], 2015c), and 
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910 (Siegel, Miller, & Jemal, 2015) respectively.  Gynecologic cancers may be further classified 
into histological subtypes (McCluggage, 2011).  For example, four common subtypes in ovarian 
cancer are serous, endometrioid, clear cell, and mucinous carcinomas (McCluggage, 2011), and 
endometrial cancer subtypes include endometrioid and nonendometrioid (Binder & Mutch, 2014) 
carcinomas.  Serous, clear cell, and undifferentiated classifications are included within the 
nonendometrioid subtype (Binder & Mutch, 2014).  
 In summary, breast and gynecologic cancers are major health concerns for women.  
Scientific advancements such as genomic profiling have shown that breast and gynecologic 
cancers are a heterogeneous group of diseases necessitating a personalized approach for selecting 
the most appropriate treatment modalities.  The implementation of genomic profiling and its 
potential to identify specific genomic alteration(s) that can be matched to specific therapies that 
target the alteration(s) is rapidly changing the field of oncology.  Given the novelty of matched 
therapy, nurses and other clinicians are unfamiliar with the symptoms patients experience and the 
impact of these symptoms on HRQOL.  This is a new and emerging field of study in 
contemporary oncology care.  
Purpose, Aims and Research Questions 
Purpose and Aims 
 The purpose of this study is to describe the characteristics of patients with breast or 
gynecologic cancer undergoing matched therapy or not matched therapy, as well as to describe 
cancer therapy-related symptom occurrence and severity, and overall HRQOL for patients 
undergoing matched therapy and not matched therapy.  Study aims are to: (a) describe the 
characteristics of the patients by type of therapy (matched, not matched); (b) describe symptom 
occurrence and severity of cancer therapy-related symptoms as well as HRQOL among patients 
receiving matched therapy and those not receiving matched therapy; (c) examine the association 
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between type of therapy (matched therapy, not matched therapy) and overall symptom 
occurrence and severity as reported on the Therapy-Related Symptom Checklist (TRSC) after 
controlling for person and health/illness factors; and (d) examine the relationship between type 
of therapy (matched therapy, not matched therapy) and HRQOL as reported on the Health-
Related Quality of Life – Linear Analogue Self Assessment (HRQOL-LASA) after controlling 
for person and health/illness factors. 
Research Questions 
 Research Question #1.  What are the characteristics (demographic data, socioeconomic 
data, length of therapy, concurrent therapy, prior lines of therapy [number and type], cancer type 
and stage, and number of comorbidities) of patients by type of therapy (matched therapy, not 
matched therapy)?  
 Research Question #2.  What is the occurrence and severity of cancer therapy-related 
symptoms as reported on the Therapy-Related Symptom Checklist (TRSC) and overall HRQOL 
as reported on the Health-Related Quality of Life – Linear Analogue Self Assessment (HRQOL-
LASA) for patients receiving matched therapy and those receiving not matched therapy?  
 Research Question #3.  What is the association between type of therapy (matched 
therapy versus not matched therapy) and overall occurrence and severity of cancer therapy-
related symptoms as reported on the TRSC after controlling for person (age) and health/illness 
factors (cancer type, cancer stage, length of therapy, number of prior lines of therapy, and 
number of comorbidities)? 
 Research Question #4.  What is the association between type of therapy (matched 
therapy versus not matched therapy) and overall HRQOL as reported on the HRQOL-LASA 
after controlling for person (age) and health/illness factors (cancer type, cancer stage, length of 
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therapy, number of prior lines of therapy, number of comorbidities, and overall symptom 
occurrence and severity)?   
Significance of the Study for Nursing 
 Concerted efforts have been made to increase the survival benefits of the therapies used 
to treat cancer, yet the impact of these therapies on the individual has traditionally been given 
less consideration.  More recently, there has been increased national attention to symptoms and 
other patient reported outcomes including QOL.  The NINR has included advancing QOL 
through symptom research as one of its five focuses for advancing the science of health (Grady 
& Gough, 2015; NINR n.d., 2016).  A major tenet of this focus is to support research that 
improves the understanding of symptoms in order to improve QOL, especially in the context of 
chronic health conditions and precision medicine, which is an approach for disease treatment and 
prevention that takes individual variability in genes, environment, and lifestyle for each person 
into account (Grady & Gough, 2015; National Institutes of Health [NIH], n.d.a.; NINR, 2016).  
Improving the QOL of cancer survivors is now listed in Healthy People 2020 objectives (Healthy 
People, 2015), and the NCI has advocated for expanding research on patient reported outcomes 
such as symptoms and QOL (Reeve et al., 2014).   
To meet these national research objectives, nursing research must be aligned with the 
most up to date practices, which in oncology includes genetic and genomic science.  Professional 
nursing organizations have proclaimed the need for nursing to incorporate genomic knowledge 
and skills into nursing practice (Hamilton, 2009), and competency and curricula guidelines now 
exist for nursing education (American Nurses Association [ANA], 2006; 2009).  The Oncology 
Nursing Society (ONS) has called for the “need for oncology nurses to integrate genetic and 





 The Symptom Management Theory (SMT), (see Figure 1) with its core concept of 
symptoms, is well matched to the quantitative research proposed in this paper and was used to 
identify and classify variables relevant to the study.  The SMT was initially developed by a 
group of nursing scientists at the University of California at San Francisco School of Nursing in 
1994 through a deductive process based on their combined scope of practice and research 
programs in chronically ill populations (Linder, 2010).  Revisions to the original were published 
in 2001 (Dodd et al., 2001), and again in 2008 (Humphreys et al., 2008).    
 
Figure 1. Symptom Management Theory conceptual framework (from Dodd et al., 2001). 
The SMT describes three key concepts of symptom management: (a) Symptom 
experience, (b) Symptom management strategies, and (c) Symptom status outcomes (Linder, 
2010).  Each concept is nested within the person, health/illness, and environment domains of 
nursing science (Humphreys et al., 2008) due to the potential influences from these domains.  
Relationships among the concepts are depicted as a dynamic process with the use of the 
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bidirectional arrows.  Effective symptom management requires attention to all three components 
(Linder, 2010). 
 The symptom experience served as one focus of the study.  Symptoms are conceptually 
defined in the SMT as “a subjective experience reflecting changes in the biopsychosocial 
functioning, sensations, or cognition of an individual” (Dodd et al., 2001 p. 669).  According to 
SMT assumptions, the gold standard for the study of symptoms is based on the perception of the 
individual experiencing the symptom and his/her self-report (Dodd et al., 2001, p. 669-670).  
This assumption guided the choice of and provides support for the instrument that was used in 
the study, the TRSC, which measured symptom occurrence and severity per patient self-report.   
Health and illness factors can have direct effects on the symptom experience (Dodd et al., 
2001).  In this quantitative study, the type of cancer therapy a patient receives falls within the 
health and illness domain.  Other variables falling within the health and illness domain that were 
included are as follows: cancer type, cancer stage, comorbidities, number of prior lines of 
therapy, and length of therapy.  Person factors can also have direct effects on the symptom 
experience by influencing the way an individual responds to the symptom experience (Dodd et 
al., 2001).  Age, ethnicity, insurance type, and drug coverage type fall within the person domain 
and were included as variables for this study.  All research questions focused on these variables 
of the symptom experience of breast and gynecologic cancer patients, which are further 
described in Chapter 2.  The third research question examined associations among these 
variables.   
 The fourth research question relates to the outcome component of the SMT.  Outcomes 
emerge from the symptom experience and include QOL (Dodd et al., 2001).  In the proposed 
study, HRQOL was used in place of QOL since it provides a narrower focus and refers to aspects 
that are related to health, illness, and treatment (Ferrans, Zerwic, Wilbur, & Larson, 2005).  
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Definition of Terms 
 Key terms have been conceptually and operationally defined.  Other terms relevant to this 
study are defined in Chapter Three.  
 Matched Therapy is conceptually defined as the matching of a specific cancer therapy 
or therapies that is/are known to target a genomic alteration(s) to the patient’s genomic 
alteration(s), which is/are found on genomic profiling.  The operational definition is the use of at 
least one drug that is known to target the genomic alteration of at least one of the patient’s 
genomic alterations found on genomic profiling.   
 Not Matched Therapy is conceptually defined as therapy or therapies used to treat 
cancer that is/are not matched to specific genomic alteration(s).  The operational definition is the 
use of drugs that are not specifically matched to genomic alterations.  Patients receiving not 
matched therapy may or may not have had genomic profiling testing.  
 Symptoms are conceptually defined as “A subjective experience in the biopsychosocial 
functioning, sensations, or cognition of an individual” (Dodd et al., 2001, p. 669).  The 
operational definition is cancer therapy-related symptom occurrence and severity as measured by 
the Therapy-Related Symptom Checklist (TRSC). 
 Health-Related Quality of Life (HRQOL) is conceptually defined as an individual’s 
perception of health-related well-being based on principle health components including the 
physical, emotional, mental, social, spiritual, and overall QOL (Bretscher et al., 1999; Ferrans, 
Zerwic, Wilbur, & Larson, 2005).  The operational definition is HRQOL (physical, emotional, 
mental, social, spiritual, and overall QOL) as measured by the Health-Related Quality of Life- 
Linear Analogue Self Assessment (HRQOL-LASA).   
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 Surgery is conceptually defined as using operations in the treatment of disease or injury 
(MedicineNet.com, 2016).  The operational definition is using surgery to treat patients with 
breast or gynecologic cancers as identified in the patient health care record.   
Chemotherapy is conceptually defined as the use of cytotoxic, systemic, and non-
specific chemical agents to kill rapidly dividing cells (ACS, 2017b).  The operational definition 
is using non-specific chemotherapeutic agents to treat patients with breast or gynecologic cancers 
as identified in the patient health care record. 
 Radiation Therapy is conceptually defined as the use of high-energy radiation to shrink 
tumors and kill cancer cells (NCI, 2010).  The operational definition is using radiation therapy to 
treat patients with breast or gynecologic cancers as identified in the patient health care record.  
  Targeted Therapy conceptually refers to drugs or other substances that block the 
growth and spread of cancer by interfering with specific molecules, or molecular targets, that are 
involved in the growth and spread of cancer (NCI, 2014).  The operational definition is using 
targeted therapy to treat patients with breast or gynecologic cancers as identified in the patient 
health care record.   
 Cancer Genomic Profiling is conceptually defined as the examination and 
characterization of DNA or RNA sequences of cancer cells which is accomplished through 
laboratory testing.  The information generated from this testing includes: a) identification of 
nucleotide bases/their order, b) copy number and sequence variants, c) mutation status, and d) 
structural changes such as chromosomal translocations and gene fusions (Wikipedia, 2017).  
The operational definition of cancer genomic profiling for this study is the genomic 
profiling of breast or gynecologic tumors using the FoundationOne Assay.  Results are used in 
practice and in the setting for this study to match patient specific therapy/therapies to 
alteration(s) identified on genomic profiling tests.   
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 Study Assumptions 
1. Symptoms are based on the perception of the individual and their self-report. 
2. Patients truthfully report their demographic characteristics, cancer therapy-related symptoms, 
and perceptions of HRQOL.  
3.  The electronic health record (EHR) documentation accurately reflects the patients’ type and 
stage of cancer, demographic information, length of therapy, and number of comorbidities. 






 Advancements in the field of genomics (the study of genes and their function) are rapidly 
changing how cancer is treated (World Health Organization [WHO], 2015).  Therapy choices are 
no longer restricted by where the primary tumor originated, but are increasingly being based on 
the genomic cancer alterations to increase specificity and efficacy.  Matched therapy, therefore, 
may translate to using therapies in combinations that are not routine, or were previously 
uncombined.  Numerous previous studies regarding cancer therapy-related symptoms and 
impacts on HRQOL have been conducted in populations that have not received matched therapy, 
including cancer treatment modalities involving surgery, chemotherapy, and/or radiation therapy.  
Currently there is limited information available concerning the symptom experience of cancer 
patients and their HRQOL while receiving therapy that is matched to their specific cancer 
genomic alterations.    
 This chapter will review the following: (a) Cancer; (b) Cancer Treatment Modalities – 
Surgery, Radiation Therapy, Chemotherapy; (c) Cancer Treatment Modalities – Precision 
Medicine, Targeted Therapy, Matched Therapy; (d) Therapy-Related Symptom Occurrence and 
Severity; (e) Symptom Measurement Tools; (f) Other Variables Influencing the Effects of 
Cancer Treatment; (g) Health-Related Quality of Life (HRQOL); and (h) Health-Related Quality 
of Life (HRQOL) Measures.  
Cancer  
 Cancer is a generic name applied to a group of disorders that involves uncontrolled 
division of body cells (ACS, 2015b; NCI, 2015f).  Cancer is characterized by one or more of the 
following alterations: sustained proliferative signaling, evasion of growth suppressors, resistance 
to cell death, replicative immortality, inducement of angiogenesis, and activation of invasion and 
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metastasis (Hanahan & Weinberg, 2011).  These alterations result in uncontrolled division of 
body cells that are due to DNA aberrations, which can be inherited (germline) or acquired 
(somatic).  Somatic mutations can occur spontaneously during an individual’s lifetime or can be 
induced by environmental (e.g. sun exposure), lifestyle (e.g. cigarette smoking), or other factors. 
The majority of cancers are due to somatic mutations versus inherited/germline mutations (ACS, 
2015b). 
 Cancer has been generally classified by the type of tissue in which the cancer originates, 
its structural pattern (histological type), and by the location where the cancer first developed 
(primary site) (NCI, 2015b).  Most cancers are also assigned a grade of 1, 2, 3, or 4, which refers 
to how abnormal the tumor cells and tumor tissue look under a microscope (NCI, 2013).  If the 
tumor cells and the structure of the tumor tissues closely resemble the normal cells and tissues, 
then the cancer is referred to as well-differentiated.  Tumors that are well-differentiated tend to 
grow and spread at a slower rate, thus are assigned a lower grade.  Conversely, cancers that have 
tumor cells and tumor tissues that do not resemble the normal cells and tissues are described as 
poorly differentiated.  Poorly differentiated tumors typically grow more rapidly, thus are 
assigned higher grades.  Tumors with higher grades are associated with a more aggressive cancer 
(ACS, 2015b).  Table 1 shows an example of a general grading system. 
Table 1 
General Cancer Grading System 
Amount of Abnormality Associated grade 
GX: Grade unable to be assessed Undetermined grade 
 
G1: Well-differentiated Low grade 
 
G2: Moderately differentiated Intermediate grade 
 
G3: Poorly differentiated High grade 
 
Table 1 Continued 
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Amount of Abnormality Associated grade 
 
G4: Undifferentiated or Dedifferentiated  High grade 
 
Note. Adapted from example of cancer grading system, NCI 2013 
 A modification of the general cancer grading system, called the Nottingham grading 
system, is used for breast cancers.  The Nottingham grading system is based on the evaluation of 
three features: (a) Tubule formation, which refers to how much of the tumor tissue has normal 
breast duct structures; (b) Nuclear grade, which is an evaluation of the size and shape of the 
tumor nuclei; and (c) Mitotic rate, which measures how many dividing cells are present to 
determine how fast the tumor cells are dividing (NCI, 2013).  Each feature is scored from one to 
three, one meaning the tumor cells look the most like normal cells, and three meaning the tumor 
cells look the most abnormal.  The scores are summed to determine the grade.  Table 2 shows the 
grades associated with the Nottingham scores.   
Table 2 
Nottingham Score and Corresponding Grades for Breast Cancer 
Total Nottingham Score Grade 
3-5 Grade 1, Low Grade 
 
6-7 Grade 2, Intermediate Grade 
 
8-9 Grade 3, High Grade 
Note. Adapted from Nottingham score in breast cancer, NCI 2013 
 Cancers are further classified according to stage.  In most cancers, the stage is based on 
four factors: (a) location of the primary tumor, (b) tumor size and extent of tumors, (c) lymph 
node involvement, and (d) presence or absence of metastasis (AJCC, 2015).  Decisions regarding 
the best way to treat each cancer diagnosis are dependent on this entire classification process.   
Cancer Treatment Modalities – Surgery, Radiation Therapy, Chemotherapy 
 National Comprehensive Cancer Network (NCCN) Guidelines have been in existence 
since 1996 to standardize the treatment of all cancer types (NCCN, 2015).  Historically, surgery, 
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radiation therapy, and chemotherapy have been the primary modalities of cancer treatment.  
Depending on the type of cancer and on the extent of the disease, one or more of these treatment 
modalities may be used.   
 Surgery.  Using surgery to remove cancer has been documented since ancient times, 
although this modality is only successful for local control of the cancer.  In other words, if the 
cancer has spread or metastasized to other areas in the body, then surgery will not be curative.  
However, surgery may be used even if the cancer has spread in order to palliate symptoms, for 
example if one or more of the tumor(s) is causing significant pain or pressure (NCI, 2015d).  
Surgery may also be performed before or after other treatment modalities such as chemotherapy 
and radiation.   
 Radiation therapy.  At the beginning of the 20th century, radiation therapy was being 
used to diagnose cancer and to treat cancer.  High energy radiation such as X-rays, gamma rays, 
and charged particles are used to treat cancer due to their ability to damage DNA directly or 
create free radicals within the cells that in turn damage DNA.  Like surgery, it is typically used 
for local control of the cancer.  Systemic radiation therapy is less common and uses radioactive 
substances that travel in the bloodstream, such as radioactive iodine for the treatment of thyroid 
cancer.  Radiation may occur before surgery to shrink the size of the cancer, during the surgery 
so that the radiation goes straight to the cancer without passing through the skin, or after surgery 
to kill any potential cancer cells that may remain (NCI, 2010).   
 Chemotherapy.  Chemotherapy is used to destroy cells that grow and divide rapidly.  
Most chemotherapies affect the process of cell division and are classified according to whether 
they are cytotoxic during active division of cells, or during the proliferative and resting phases of 
division (Payne & Miles, 2008).  Chemotherapies destroy cancerous cells and normal cells and 
therefore are associated with significant side effects.  Similar to radiation therapy, chemotherapy 
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may be used to shrink a tumor before surgery – called neoadjuvant chemotherapy, or may be 
used after surgery to destroy potential remaining cancer cells – called adjuvant chemotherapy 
(NCI, n.d.a).  Neoadjuvant and/or adjuvant chemotherapy are frequently used in non-metastatic 
breast and gynecologic cancers (Gradishar & Salerno, 2016; Wright et al., 2016).  Chemotherapy 
can also be used to control the progression of the cancer in cases when the disease has 
metastasized to other parts of the body.   
 Chemotherapy regimens may include the use of a single chemotherapy drug or a 
combination of chemotherapy drugs, the latter being more common.  Combining chemotherapies 
that have different mechanisms of action is typically more effective since the cancer cells are 
attacked in several different ways (ACS, 2017b).  For example, alkylating chemotherapy agents 
are used in certain breast cancer and gynecologic cancer chemotherapy regimens to directly 
damage the deoxyribonucleic acid (DNA) of the cancer cells.  Alkylating agents can be 
combined with anthracycline chemotherapy agents, which interfere with cancer cell DNA 
replication, and/or mitosis in the M phase of the cell cycle (ACS, 2017b).  These are a few 
examples of the many classes of chemotherapeutic drugs used.   
The length of time a chemotherapy regimen is given as well as the frequency of the 
regimen is highly dependent on the classes of drugs used and the intent of the outcome of the 
treatment of the cancer (curative, palliative).  In a neoadjuvant or adjuvant setting where the 
intent of treatment of the cancer is curative, the regimen is usually given every two to three 
weeks.  Many different chemotherapy regimens exist for metastatic cancer; a regimen may be 
given every week, every two to three weeks, or even every four weeks.  The total length of time 
a typical chemotherapy regimen is administered for breast cancer in the neoadjuvant or adjuvant 
setting is 20 to 24 weeks.  If the breast cancer is the HER2 subtype, a type of targeted therapy 
called trastuzumab which specifically targets the HER2 proteins is given for an additional nine 
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months after the chemotherapy is completed.  The length of time a typical chemotherapy 
regimen is administered in the neoadjuvant or adjuvant setting in gynecologic cancers is 18 
weeks.  In the metastatic setting, chemotherapies are given indefinitely depending on the 
tolerability of the regimen and the disease response to the regimen (NCCN, 2016; 2017).   
 Disadvantages of treatment with surgery, radiation therapy and chemotherapy.  As 
discussed above, surgery and radiation therapy are effective treatments of cancer only in the case 
of local control.  If the cancer has spread, then surgery and radiation therapy become palliative 
rather than curative in nature.  The disadvantage of treatment protocols using chemotherapy is 
that the protocols do not acknowledge the heterogeneity of tumors.  For example, the same 
chemotherapy regimen is used to treat patients with ovarian cancer regardless of whether they 
have a serous subtype, endometrioid, clear cell subtype, or mucinous subtype of ovarian cancer.  
Patients with the clear cell and mucinous ovarian cancer subtypes are typically resistant to 
chemotherapy at baseline and both are associated with worse prognoses (Raja, Chopra & 
Ledermann, 2012).  Approximately 75% of patients with the serous subtype of ovarian cancer 
will achieve remission with initial chemotherapy yet half of these patients will have recurrent 
disease within two years (Ozols, 2006).  Many times, the exact same chemotherapies are 
administered when the disease recurs, with much smaller rates of remission (Ozols, 2006).      
 The treatment of breast cancer is advanced in terms of tailoring therapies to the different 
subtypes and corresponding features.  Nevertheless, breast cancer is still the second leading 
cause of cancer-related death among American women (ACS, 2015a).  Breast cancer has long 
been recognized as a heterogeneous disease, and data compiled from comprehensive genomic 
profiling results have led to the now accepted belief that no two breast cancers possess the same 
genomic alterations (Natrajan, 2015).  As a result of this diversity, therapies will have varying 
effects in patients.  To illustrate, luminal subtypes of breast cancer have higher expressions of 
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ER/PR, and thus are predicted to respond to endocrine therapy.  Endocrine therapy blocks the 
tumor’s ability to use estrogen and/or progesterone for survival and proliferation.  However, 
approximately 50% of patients that have metastatic breast cancer are resistant to endocrine 
therapy at baseline, and those that are not will likely acquire resistance during ongoing use of the 
therapy (Osborne & Schiff, 2011).  
 Although cancer survival rates have improved using surgery, radiation therapy, and 
chemotherapy, cancer, in many cases, remains an incurable disease.  Surgery and radiation 
therapy are still only effective in early-stage cancers or in palliative settings.  Some cancer cells 
become resistant to chemotherapy, while other cancer cells are inherently resistant at baseline.  
Consequently, patients with the same primary tumor and the same type of therapy can have very 
different outcomes.  Moreover, all of the treatment modalities, especially chemotherapy, can 
cause significant side effects (DeVita, Lawrence, & Rosenberg, 2011; Reeve et al., 2014).  This 
has fueled the desire to develop a more personalized and targeted approach to treat cancer in 
order to maximize the risk/benefit ratio.  
Cancer Treatment Modalities - Precision Medicine, Targeted Therapy, Matched Therapy   
 Precision Medicine.  Precision medicine is a general term for the treatment of diseases 
that takes into account individual variability in genes, environment, and lifestyle for each person 
(NIH, n.d.a).  Funding to support precision medicine called the “Precision Medicine Initiative” 
was announced by former President Obama in 2015.  This new initiative, is expected to 
accelerate biomedical discoveries that will provide clinicians with new tools, knowledge, and 
therapies that can be applied to patients for the treatment of diseases on an individual basis.  The 
use of precision medicine is most advanced in the treatment of cancer, which is largely due to the 
fact that cancer is a known disease of the genome (NIH, n.d.b.).  Research over the past two 
decades has focused on cancer therapies that can directly target cancerous cells.   
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 Targeted therapy.  Targeted therapies were introduced into routine oncology practice 
during the late 1990’s.  A targeted therapy is generally considered to be chemotherapy, but their 
mechanisms of action are different.  Whereas chemotherapy primarily acts on rapidly dividing 
normal and cancerous cells (cytotoxic), targeted therapies block the proliferation of cancer cells 
by interfering with specific molecules required for tumor growth (cytostatic) (Gerber, 2008). 
Targeted therapies can block cancer cell proliferation in a number of ways such as interfering 
with the function of receptors, ligands, or cell surface markers (Belum, Cercek, Sanz-Motilva, & 
Lacouture, 2013).  Depending on their mechanism of action, many types of targeted therapies 
exist and, while not an exhaustive list, include: a) Signal transduction inhibitors, which inhibit 
proteins used for signaling cancer cell growth; b) Angiogenesis inhibitors, which reduce tumors 
from producing new blood vessels; c) Monoclonal antibodies, which attack a specific target on 
cancer cells; and d) Proteasome inhibitors, which stop the proteasomes in the cancer cells from 
breaking down proteins that inhibit apoptosis (Belum et al., 2013; Gerber, 2008; NCI, 2014).   
 One of the earliest examples of a targeted therapy is trastuzumab, which is an antibody 
directed against the HER2 receptor (Leyland-Jones, 2002; Slamon et al., 2001).  When HER2 
dimerization occurs, tyrosine kinase phosphorylation is activated, thereby initiating multiple 
signaling events that lead to cell survival and proliferation, and inhibition of apoptosis (Leyland-
Jones & Smith).  Although the mechanism of action is disputed, it is thought that trastuzumab 
binds to the HER2 receptor once it is dimerized, thus eliciting an immune response and 
inhibiting the signaling cascade, that ultimately results in tumor cell death (Leyland-Jones, 2002; 
Leyland-Jones & Smith, 2011).  It is proposed that the mitogen-activated protein-kinase and 
phosphatidylinositol 3-kinase and Akt pathways are inhibited as a result of trastuzumab, both of 
which are involved in fundamental cellular processes including cell survival, proliferation, and 
apoptosis (Arnould et al., 2006).  Since the Food and Drug Administration (FDA) approval of 
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trastuzumab, examining breast cancer cells for HER2 amplification has become a routine 
pathology test.  Detection of HER2 amplification can be accomplished by a) 
Immunohistochemical stains (IHC), in which special stains or markers are used to identify the 
HER2 protein; or b) Fluorescent in situ hybridization (FISH), in which fluorescent pieces of 
DNA that stick to copies of the HER2 gene are counted (ACS, 2017a).  The survival rate of 
women with HER2 amplified breast cancers has dramatically improved because of trastuzumab 
(Untch et al., 2008).    
 Trastuzumab is only used when HER2 amplification is detected, but other targeted 
therapies may be used without a corresponding detectable target.  For instance, everolimus is a 
drug that inhibits the activation of the mammalian Target of Rapamycin (mTOR), which is a key 
regulatory kinase (NCI, n.d.b).  A kinase is an enzyme that modifies other proteins through 
phosphorylation, and are known to regulate the majority of cellular pathways (Manning, 2016).   
Everolimus is approved for treatment of breast cancer, renal cell cancer, and certain soft tissue 
sarcomas as part of the standard NCCN guidelines due to the increased percentage of mTOR 
alterations found in these cancers.  Thus, everolimus is being used as therapy for these cancers 
due to clinical experience instead of a specific genomic profiling data.  However, if mTOR 
alterations are not the driving mutations in these cancers, which they are not universally, then 
everolimus is less likely to be effective.  Genomic profiling is able to identify the individual’s 
specific tumor alteration(s) enabling the precise use of agents that target the alteration(s).  
 Matched therapy.  Matched therapy refers to matching a specific cancer therapy or 
therapies that is/are known to target a specific genomic alteration(s) found on cancer genomic 
profiling.  Matched therapy represents a major paradigm shift in the treatment of cancer, which 
has evolved over the past several decades.  Data from research suggest that each cancer has its 
own genomic signature, with some features specific to the tumor and other features common to 
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multiple types of cancers (Collins & Varmus, 2015).  This heterogeneity is what is believed to be 
responsible for the differences in responses to the same type of therapy among patients with the 
same histologic type (McDermott et al., 2011).  Genomic profiling has the capability of revealing 
specific genomic alterations and thus, tumor heterogeneity.   
 It is now possible and feasible to perform genomic profiling on a patient’s tumor in 
routine clinical practice, which has the potential to find their specific genomic alterations.  
Genomic profiling is performed using  technologies now referred to as next generation 
sequencing and high-throughput sequencing, in which millions of DNA strands can be 
sequenced in parallel (Nature.com, 2015).  Today’s testing procedures allow examination of the 
DNA sequence of just a few genes up to many genes, which may lead to the identification of an 
alteration that could be driving the cancer and/or affecting cancer signaling pathways (National 
Genetics and Genomics Education Centre, n.d.).  Cancer Signaling Pathways is when a group of 
molecules in a cell work together to control one or more abnormal functions, such as cell 
proliferation.  In normal cell function, signaling pathways are key for homeostatic processes in 
which an initial molecule in a pathway receives a signal, and then activates other molecules.  
This process is repeated until the activation of the necessary molecules is completed and the cell 
function is carried out.  In cancer, due to genomic alterations, the signaling pathways are 
abnormal (NCI, n.d.a; Yap, Omlin, & Bono, 2013).  The aim of genomic profiling is to detect the 
tumor’s driving alteration(s) since they are responsible for the proliferation and survival of the 
cancer cell (McDermott et al., 2011).  The ultimate goal is to match therapies that potentially 
target and interfere with that particular alteration and/or cancer cell-signaling pathway. 
An example of a cancer genomic profile test used in clinical practice is the CLIA-
certified FoundationOne assay, which uses next generation sequencing, is provided by the 
company Foundation Medicine, and has been available since October 2013.  Some insurance 
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companies cover the cost of the FoundationOne assay and, if insurance denies coverage, the 
company works with the individual to complete the testing at a reasonable price.  Besides the 
FoundationOne assay, other cancer genomic profile tests exist, but each have a slightly different 
approach in terms of what kind of alterations are reported, and how the test is performed.  
  Results obtained from genomic profiling may also indicate that the tumor is sensitive or 
resistant to a certain type of chemotherapy.  For instance, an alteration called ARID1A may 
indicate that that a tumor is resistant to a class of chemotherapies called platinums.  Another 
alteration, called TOP2A, may indicate a tumor is sensitive to a class of chemotherapies called 
anthracyclines.  Finding alterations indicating sensitivity or resistance to a chemotherapy is less 
common in practice, thus alterations are predominantly matched to therapies that specifically 
target the alteration.     
 Prospective studies comparing matched therapy to not matched therapy are ongoing or in 
development, but retrospective studies have indicated that the matched therapy yields superior 
outcomes (Schwaederle et al., 2015; Tsimberidou et al., 2012; 2014).  Schwaederle et al. (2015) 
performed a retrospective study evaluating the clinical outcomes of N = 392 patients with a 
variety of cancer types who had genomic profile testing on their cancer tumor.  The most 
common primary tumor sites were gastrointestinal (23%) followed by breast (21%), brain (14%), 
gynecologic (8%), head and neck (8%), and hematologic (8%).  The remaining 18% of patients 
had melanoma, lung, and other cancers.  Of the N = 246 patients evaluated, n = 53 patients were 
treated with agents that were matched to genomic alterations found on genomic profiling.  The 
researchers showed that progression free survival (PFS) was significantly longer in patients who 
received matched therapy versus those who did not (p = 0.042).  Progression free survival refers 
to the time elapsed between initiation of any type of treatment modality and tumor progression or 
death from any cause (NCI, n.d.a) and is a common endpoint used in cancer clinical trials 
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observing treatment modality efficacy (Booth & Eisenhauer, 2012).  The measure allows for a 
smaller sample size and shorter follow up time period.  Because hormone positive and HER2 
positive breast cancer patients were included in the matched therapy group, a Cox regression 
analysis was performed including matched therapy vs. non-matched and breast histology 
(hormone and HER2 status) as variables.  The matched therapy approach was the only variable 
independently predicting a longer PFS (p = 0.028) (Schwaederle et al., 2015).   
Researchers in a Phase I program at MD Anderson Cancer Center examined the 
outcomes of patients receiving matched therapy based on genomic profiling (this genomic 
profiling test covered 20 genes) versus therapies that were not matched (Tsimberidou et al., 
2012; 2014).   Two separate analyses were performed.  Patients in both analyses had advanced or 
metastatic disease, had exhausted other therapy options, and had been referred to the Phase I 
Program at the University of Texas MD Anderson Cancer Center for treatment of their cancer.  
Therapy was considered matched if a drug known to inhibit the activity of at least one of the 
patient’s tumor alterations was used.  Therapy that did not satisfy this definition was considered 
unmatched.  In the first analysis, 175 patients were treated with matched therapy while 116 
received not matched therapy (Tsimberidou et al., 2012).  Breast cancer patients represented 6% 
of the sample (n = 14 matched; n = 2 not matched) while gynecologic cancers represented almost 
10% (n = 17 matched; n = 11 not matched).  The majority of the sample was comprised of 
patients with melanoma (25%), colorectal (21%), and thyroid (12%) cancers.  Endpoints 
included overall response rate, which is complete response (complete resolution of disease) plus 
partial response (≥ 30% reduction in disease but < 100%), and overall survival.  Matched therapy 
was associated with a significantly higher overall response rate (p < 0.001) and longer survival (p 
= 0.017).  Multivariate analysis found that in patients with at least one genomic alteration, 
matched therapy was an independent factor predicting overall response (p = 0.001; OR 6.33) 
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(Tsimberidou et al., 2012).  To validate these findings, data from an additional 379 patients 
enrolled in the Phase I program between 2011 and 2012 were analyzed (Tsimberidou et al., 
2014).  Patients with colorectal (22%), lung (12%), ovarian (9%), melanoma (9%), and breast 
(9%) cancers represented a majority of the sample.  The validation analysis revealed that patients 
receiving matched therapy (n = 143) had a significantly higher overall response rate (p < 0.001), 
and longer survival (p = 0.04) than patients receiving not matched therapy.  Multivariate analysis 
found matched therapy to be an independent factor predicting overall response (p = 0.015; OR 
1.91).  
To date, one prospective clinical trial has been published with the primary aim of 
establishing the feasibility of identifying genomic alterations in breast cancer patients, with the 
intention of providing targeted therapy matched to the individuals’ alterations (Andre et al., 
2014).  In this trial, breast cancer patients with metastatic disease underwent a biopsy of their 
cancer, which was subsequently analyzed for genomic alterations.  Therapeutic decisions were 
then made based on the identified alterations.  Among the 423 patients initially enrolled, 195 
patients had at least one genomic alteration that could be matched to a targeted agent.  Of the 
195, 43 patients had been on matching therapy for at least 16 weeks and were able to be 
evaluated for disease response at the time the data were reported.  Among these 43 patients, four 
patients had an objective response to therapy while the remaining had stable disease, indicating 
that the tumor(s) did not grow or shrink (Andre et al., 2014).  Objective response was 
operationally defined in the study as a reduction in tumor size on imaging such as CT scan.  
Although the results may seem underwhelming, it should be noted that the patients included in 
this study had advanced disease and were heavily pretreated, thus decreasing the chance of any 
response in this setting.  Moreover, it was the first prospective trial to show that matching 
therapy based on an individual’s genomic profile was feasible.     
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 In summary, the treatment of cancer is increasingly being personalized and based on the 
genomic alterations exhibited by the tumor versus the primary site of the tumor.  Recent research 
show promising results with this more personalized approach, and prospective trials are ongoing 
to validate the findings.   
Cancer Therapy-Related Symptom Occurrence and Severity 
 In general, cancer therapy is associated with frequent and potentially severe toxicities and 
associated symptoms.  A systematic literature review examining the prevalence of symptoms in 
patients with varying cancer diagnoses undergoing treatment of their cancer identified 47 
separate symptoms across 21 studies (Miller-Reilly et al., 2013).  Of the 47 symptoms, a distinct 
set of symptoms emerged that were common across cancer types including fatigue, insomnia, 
anorexia, dry mouth, pain, cognitive changes, and nausea.  Building upon this review, the NCI’s 
Symptom Management and Health-Related Qualify of Life Steering Committee set out to 
identify a core list of symptoms to assess across oncology trials that were 1) present across 
diverse cancer populations, 2) impacted health outcomes and HRQOL, and 3) could be attributed 
to the disease or to cancer treatment modalities (Reeve et al., 2014).  The methods employed to 
accomplish this included expanding on the Miller-Reilly (2013) literature review, analyzing two 
NCI clinical trial databases and four other large datasets across the United States and Europe, 
and forming an expert panel to review the evidence and provide consensus.  This large 
undertaking culminated in the recommendation that a core set of 12 symptoms be considered for 
inclusion in oncology clinical trials.  The 12 symptoms include fatigue, insomnia, pain, anorexia, 
dyspnea, cognitive problems, anxiety, nausea, depression, sensory neuropathy, constipation, and 
diarrhea (Reeve et al., 2014).  It should be noted that these data used to conclude this core list of 
symptoms were collected between the years 2000-2011.  While some of the core symptoms are 
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likely related to the disease, many are therapy-related.  New therapies may produce different 
symptoms that are not part of the core assessment, which can lead to bias and under-reporting. 
 Numerous individual studies have quantified the number of these cancer therapy-related 
symptoms across cancer types (Chen & Tseng, 2006; Janz et al., 2007; Kenne-Sarenmalm, 
Ohlen, Jonsson, & Gaston-Johansson, 2007; Kirkova et al., 2011; Lopez, Williams, & Larkin, 
2015; Spichiger et al., 2011).  In a large study of breast cancer patients (N=1372), Janz et al. 
(2007) found that the average number of symptoms experienced by the participants who had 
completed surgery and radiation and/or chemotherapy was seven.  In this study, the European 
Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC 
QLQ-C30) and the Breast Cancer-Specific Quality of Life Questionnaire (QLQ-BR23) were 
used to assess symptoms.  Both the EORTC QLQ-C30 and QLQ-BR23 include symptom 
domain-specific questions within a QOL assessment, but the QLQ-BR23 has added breast cancer 
specific items such as body image, sexual functioning, and breast specific-symptoms (e.g. pain, 
lymphedema) (Janz et al., 2007).  Spichiger et al. (2011) assessed the number and type of 
therapy-related symptoms longitudinally using the Memorial Symptom Assessment Scale 
(MSAS) in a small sample of patients (N=58) with lymphoma, lung, breast, or colorectal cancer 
receiving chemotherapy and found the number of symptoms experienced to be as high as 14.  
Spichiger and colleague’s (2011) findings were corroborated by Keene-Sarenmalm et al. (2007), 
who also found that the average number of symptoms experienced when measured by the MSAS 
was 14 in a sample (N = 56) of breast cancer patients on chemotherapy or radiation therapy.  
Similarly, Chen and Tseng (2006) found that the average number of symptoms experienced by 
patients with a variety of cancer diagnoses receiving chemotherapy (N = 329) was seven.  In this 
secondary analysis of cross-sectional data study, the M.D. Anderson Symptom Inventory 
(MDSAI) was used to assess the cancer therapy-related symptoms.  A more recent cross-
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sectional study by Williams, Mowlazadeh, Sisler, and Williams (2015a) used the TRSC to assess 
symptoms in a sample of (N = 100) patients with varying cancer types who were receiving 
chemotherapy and/or radiation and found the mean symptoms reported to be eight.  
 Huang et al. (2013) conducted a study among a sample (N = 121) of breast cancer 
patients with HER2 overexpression aimed at assessing potential differences in symptoms during 
therapy with chemotherapy and targeted cancer therapy (trastuzumab).  Patients in this study 
received 12 weeks of chemotherapy, followed by 12 weeks of chemotherapy and trastuzumab 
(targeted therapy) combined, followed by one year of trastuzumab (targeted therapy) alone.  Data 
on cancer therapy-related symptoms were collected using the MDASI at baseline (prior to any 
therapy), and at four weeks, and twelve weeks after initiation of the therapy in each group.  
Results showed no significant differences in symptom occurrence and severity among patients 
receiving chemotherapy, combined therapy, or trastuzumab alone (Huang et al., 2013).  An 
important limitation of this study is that patients received the therapies sequentially, meaning 
those receiving chemotherapy and trastuzumab combined had prior experience with 
chemotherapy, and those receiving trastuzumab alone had prior experience with chemotherapy 
alone and chemotherapy and trastuzumab combined, which were not accounted for in the 
analysis.  These results are contrasted with prior studies showing that patients treated with 
chemotherapy and trastuzumab combined or trastuzumab alone experienced less severe 
symptoms than those receiving chemotherapy alone, particularly in regard to fatigue (Osoba, 
Slamon, Burchmore, & Murphy, 2002; Rugo, Brammer, Zhang, & Lalla, 2010).  
Clearly cancer therapy-related symptoms are pervasive, although all of these studies but 
one (Huang et al., 2013) relate to symptoms experienced by patients undergoing chemotherapy.   
The study by Huang et al. (2013) compared chemotherapy to targeted therapy (e.g. trastuzumab), 
however, the use of trastuzumab is standard when HER2 is overexpressed.  The symptoms 
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experienced by a broader range of patients who are on matched therapy based on comprehensive 
genomic profiling, needs to be examined.   Matched therapy based on genomic profiling results 
involve using therapies that have not been extensively studied in combination or may use 
therapies at different doses.  Currently the symptom experience of patients receiving therapies 
that are matched based on genomic profiling results is largely unknown. 
Reviewing studies that examine the prevalence of symptoms in matched cancer therapy is 
challenging for several reasons; the largest being many of the published clinical trials using 
targeted therapies may not have been specifically matched to genomic profiling results.  This is 
emphasized in a meta-analysis conducted by Niraula et al. (2012), which analyzed serious 
toxicities of newly approved cancer drugs (including chemotherapy and targeted therapies) 
between January 2000 and December 2010.  Findings showed that therapy-related toxicities were 
more severe with the newly approved therapies (p < 0.001) many of which were targeted 
therapies (Niraula et al., 2012).  The authors did not disclose whether any of the therapies used 
were matched to genomic profiling results.  However, given the time frame (2000-2010) of this 
study, it is unlikely that genomic profiling was routinely being performed prospectively.  Thus, it 
is currently unclear if the occurrence or severity of cancer therapy-related symptoms will differ 
when therapies are matched based on genomic profile testing.   
 Gaining knowledge about symptoms experienced by patients may guide clinicians in 
their management.  For instance, some symptoms/side effects (e.g. skin rash) have been 
correlated with improved responses to specific therapies, especially when they are “on-target” or 
matched (Dy & Adjei, 2013; Liu & Kurzrock, 2014).  Accordingly, it is crucial to begin to 
examine symptom occurrence and severity of patients receiving matched therapy, which can 
assist in identifying potential risks and benefits, and will ultimately contribute to symptom 
science in the context of current oncology care.   
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Symptom Measurement Tools 
 Studies that have examined cancer therapy-related symptoms have used a variety of 
measurement tools, which can be global, condition-specific, or symptom-specific (Ferrans et al., 
2005).  Since cancer patients, regardless of the cancer type, typically experience multiple 
symptoms simultaneously, measures that capture the most commonly experienced symptoms, are 
easy for patients to understand and complete, are valid and reliable, and improve assessment and 
control of symptoms are particularly useful (Kirkova et al., 2006).  A brief summary of the more 
commonly used tools in oncology are discussed.    
 M.D. Anderson Symptom Inventory.  The M.D. Anderson Symptom Inventory 
(MDASI) is a brief measure of the severity of cancer-related symptoms and their impact on the 
individual (Cleeland et al., 2000).  Thirteen symptoms common among all cancer types are listed 
on the MDASI in addition to six items that measure how symptoms have interfered with the 
individual’s life.  The MDASI has demonstrated good psychometric properties with Cronbach’s 
alpha reported as ranging from 0.82 - 0.94, and construct and discriminant validity indicated by 
inverse correlations with performance status (Cleeland et al., 2000).  Other versions have been 
developed and validated for a variety of cancer types (Jones et al., 2013).   
 Memorial Symptom Assessment Scale.  The Memorial Symptom Assessment Scale 
(MSAS) evaluates the frequency, severity, and distress of 32 physical and psychological 
symptoms (Portenoy et al., 1994).  Three symptom subscales have been identified in the MSAS 
including the mood-cognitive symptom subscale, the sickness behavior subscale, and the 
treatment-related symptom subscale.  The MSAS has been used in various clinical trials to assess 
symptom distress but has been criticized for its length and complicated ratings (Cleeland et al., 
2000).   
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Oncology Treatment Toxicity Assessment Tool.  In 1994, Youngblood, Williams, 
Eyles, Waring, and Runyon developed a self-report checklist, the Oncology Treatment Toxicity 
Assessment Tool (OTTAT), after noticing a significant underreporting of symptoms during 
treatments for cancer with the usual assessment method.  The original study compared the 
OTTAT, a 37-item self-report instrument rating symptom severity on a scale from zero to four 
(four being the most severe) to the usual assessment.  Findings showed that the number of 
symptoms reported with the usual assessment (Mean = 1.5; SD = 1.6; range = 0-9) was 
significantly lower than the mean number of symptoms reported, with the OTTAT (Mean = 11.5; 
SD = 8; range = 0-37; p = 0.001).  The OTTAT was found to be inversely correlated with the 
Quality of Life Index, (QLI) developed by Ferrans (1992) and Padilla et al. (1983).   
Therapy-Related Symptom Checklist.  In subsequent instrument development, a 
principal components analysis reduced the OTTAT into the 25-item checklist that was named the 
Therapy-Related Symptom Checklist (TRSC).  The OTTAT and the TRSC are highly correlated 
(r = 0.97) (Williams et al., 1997; 2001; 2014).  The TRSC has fourteen subscales; two subscales 
contain ‘clusters’ of four items each.  The Fatigue subscale consists of the items feeling sluggish, 
depression, difficulty concentrating, and difficulty sleeping.  The Eating subscale includes the 
TRSC ‘cluster’ symptoms of taste change, loss of appetite, weight loss, and difficulty 
swallowing.  A three-item subscale or ‘cluster’, designated as Oropharyngeal, includes sore 
mouth, sore throat, and jaw pain.  The remaining three subscales or ‘clusters’ include two items 
each: Nausea (nausea and vomiting), Fever (fever and bruising), and Respiratory (cough and 
shortness of breath).  Eight of the subscales are single item scales (Pain, Numbness in Fingers 
and/or Toes, Bleeding, Hair Loss, Skin Changes, Constipation, Soreness in Vein, and Decreased 
Interest in Sexual Activity).  Like the OTTAT, symptom severity is rated on a scale from zero to 
four, with four being the most severe.  
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Multiple studies using the TRSC have been conducted within the United States, as well 
as in Europe, Asia, and Puerto Rico.  The samples included in these studies were all receiving 
not matched therapy.  For example, Williams et al. (2006a) conducted a descriptive study with 
adults (N = 37) receiving chemotherapy or radiation therapy for breast cancer, head and neck 
cancer, leukemia, or lymphoma at a Midwestern cancer center.  Results showed that 15 patients 
reported 17 of the 25 symptoms or more on the TRSC.  Patients receiving chemotherapy 
generally experienced more severe symptoms in the following TRSC subscales: Fatigue, Nausea, 
Eating, Pain, Hair loss, Numbness in fingers/toes, and Constipation (Williams et al., 2006a).  
Patients receiving radiation therapy were noted to have more severe symptoms in the following 
subscales: Eating, Fatigue, Skin changes, Oropharynx, Constipation, and Decreased interest in 
sexual activity.  This study was replicated in cancer centers in China (Williams et al., 2010b), the 
Philippines (Williams et al., 2010a), and Thailand (Piamjariyakul et al., 2010) with appropriate 
translation methods.  Findings in each study were similar to the results from the Midwestern, 
United States study in regard to symptom occurrence and severity.  For example, the study 
completed in China examined patient-reported symptoms in N = 222 patients receiving 
chemotherapy and/or radiation therapy for a variety of cancers including breast cancer, 
gastrointestinal tract cancer, lung cancer, gynecologic cancers, and head and neck cancer 
(Williams et al., 2010b).  Patients receiving combined chemotherapy and radiation therapy 
reported more symptoms with greater severity on the 25-item TRSC than those receiving either 
therapy alone (F = 3.08, p < .05) while patients on either treatment modality reported severe 
symptoms on the TRSC subscales of Eating, Oropharynx, Nausea, Fatigue, and Pain (Williams 
et al., 2010b).  The study in Manila, Philippines, examined N = 100 patients undergoing 
combined radiation therapy and chemotherapy or chemotherapy alone for the following cancers: 
breast cancer, gynecologic cancers, lung cancer, colon/rectal cancer, and head and neck cancer 
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(Williams et al., 2010a).  Again, patients on the combined radiation and chemotherapy reported 
greater symptoms with higher severity on the 25-item TRSC, while 30% of the sample overall 
reported the occurrence of at least 22 symptoms.  Piamjariyakul et al (2010) used the TRSC to 
examine patient-reported symptoms in a sample of N = 202 patients in Thailand receiving 
chemotherapy and/or radiation therapy for gastrointestinal tract cancers, head and neck cancer, 
lung cancer, breast cancer, and gynecologic cancers.  As in the other studies, results showed that 
patients receiving the combined radiation and chemotherapy reported more symptoms with 
greater severity (F = 7.2; p < 0.01) on the 25-item TRSC, with more severe symptoms reported 
in the Eating, Oropharynx, Nausea, and Fatigue subscales (Piamjariyakul et al., 2010).  The 
TRSC was also reported to have good reliability and validity in each translated language.  
Originally developed in paper format, online versions have been used (Heinze et al., 2015) and 
currently the TRSC is being piloted in a variety of electronic health applications (Williams et al., 
2015b).  Additionally, the TRSC has been calibrated for a pediatric version, the Therapy-Related 
Symptom Checklist-Children (TRSC-C) (Williams et al., 2012; Williams et al., 2014). 
 Summary of Symptom Measurement Tools.  There are several limitations of the 
measures discussed.  The MSAS has been criticized for its length and its complicated rating 
method (Cleeland et al., 2000; Williams et al., 1997; 2000; 2001).  The MDASI is shorter and 
easier to complete, but the limited number of symptoms may not adequately capture the range of 
symptoms experienced by the patient.  The TRSC (a precursor of the OTTAT) is shorter than the 
MSAS, and includes spaces at the bottom of the checklist that allow patients to write in 
additional symptoms and rate their severity.  None of the symptom measurement tools discussed 





Other Variables Influencing Effects While Receiving Treatments for Cancer  
This section will discuss factors or variables that may influence symptom 
occurrence/severity while receiving treatment for cancer, as reported in the literature.  These 
factors include age, cancer stage, cancer type, length of therapy, prior cancer therapies, and 
comorbidities.  
Age.  Age as a factor in the experience of symptoms among cancer patients has been 
shown in several studies (Cataldo et al., 2013; Kirkova, Rybicki, Walsh, & Aktas, 2012; Smith et 
al., 2013).  In a secondary analysis of three separate studies regarding symptom assessment in 
oncology patients, older patients (≥ 60 years of age) reported significantly lower occurrence rates 
of symptoms, severity of symptoms, frequency, and distress of symptoms when compared to 
patients that were ≤ 60 years of age (Cataldo et al., 2013).  Multiple symptoms were reported 
among adolescents and young adults through a population-based survey of patients aged 15 - 39 
years of age (Smith et al., 2013).  Eighty-five percent of respondents reported experiencing at 
least one symptom, and 51% reported experiencing three or more symptoms (Smith et al., 2013).  
Kirkova et al. (2012) also found age to be an important variable in assessing differences in 
symptom prevalence in patients with cancer while conducting a secondary analysis of a symptom 
database.  The eight most frequent symptoms found among N = 1000 patients decreased in 
prevalence with older age (Kirkova et al., 2012) 
Stage of disease.  Stage of disease has been shown to influence the symptom experience.  
Patients with advanced cancer have been found to experience multiple symptoms (Chen & Lin, 
2007; Fan, Filipczack, & Chow, 2007; Walsh, Donnelly, & Rybicki, 2000), which can be 
attributed to the combined effects of the disease and the treatment of the disease.  Interestingly, 
an analysis by Valeberg and Grov (2013) revealed that symptom burden was basically equal 
when comparing cancer patients that were in the curative phase versus palliative phase.  The 
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authors concluded that this could be related to the acute symptoms experienced by the patients in 
the curative phase group, who were undergoing chemotherapy (Valeberg & Grov, 2013).  
Additionally, the number of patients within the curative phase was relatively small (n = 32) and 
may indicate an inadequately powered study.  Other studies have associated a higher symptom 
burden in advanced stages of cancer (Kirkova et al., 2011; Walsh, et al., 2000).  Patients with 
advanced disease have higher disease related symptoms and have received multiple treatment 
modalities for their cancer thereby leading to increased side effects and symptoms. 
Cancer types.  Traditionally different cancer types have received different cancer 
therapy regimens yet the symptoms experienced among patients overlap.  The NCI Symptom 
Management and Health-Related Quality of Life Steering Committee previously mentioned 
identified additional ovarian cancer specific symptoms: abdominal pain, bloating, cramping, fear 
of recurrence, indigestion, sexual dysfunction, vomiting, weight gain, and weight loss.  The NCI 
recommends adding the 12 core symptoms previously discussed, and eight additional symptoms 
in ovarian cancer as patient reported outcomes in cancer clinical trials, which will allow for the 
consistent assessment of common and relevant symptoms and comparisons across trials 
(Donavan et al., 2014).  The TRSC addresses a majority of these symptoms, and patients can add 
additional symptoms in with the space provided at the bottom.  
Length of therapy.  Intuitively, length of therapy, or how long an individual has been 
receiving cancer therapy, will influence symptom occurrence and severity.  Spichiger et al. 
(2011) evaluated symptom prevalence of patients undergoing chemotherapy at three time points - 
prior to the initiation of chemotherapy, one week prior to the third cycle of chemotherapy and 
one week prior to the fourth cycle of chemotherapy.  The second and third time points translate 
to approximately eight to 11 weeks, and 11 to 15 weeks post initiation of chemotherapy, 
respectively.  Results from the study showed a significant increase in symptoms over time.  This 
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has been corroborated in other observational studies (Servaes, Verhagen, & Bleijenberg, 2002; 
Williams et al., 1997).  Also, patients with metastatic or advanced stages of disease require 
chronic treatment of their cancer, which in conjunction with the disease can lead to accumulated 
symptoms.  However, other studies have found an improvement in certain symptoms over time 
(Visser, Smets, Sprangers, & de Haes, 2000) although this may be attributed to the symptom-
management interventions performed (Dujit, Faber, Oldenburg, va Beurden, & Aaronson, 2011; 
Given et al., 2002; Williams et al., 2013; Williams et al., 2011).     
Prior lines of cancer therapy.  Prior lines of therapy likely influence symptom 
prevalence due to the accumulated therapy-related toxicities, and may also indicate advanced 
disease.  Lewis et al. (2015) for example found that neuropathy, a common therapy-related 
symptom, was significantly higher among patients (N = 3106) that had received prior 
chemotherapy for a variety of cancers.  Boland et al. (2013) examined symptom prevalence in a 
small sample (N = 32) of patients with multiple myeloma who had received a median of three 
prior lines of chemotherapy.  The patients were found to have a high symptom burden, which 
impacted physical functioning and HRQOL (Boland et al., 2013).  Evaluating data from clinical 
trials that involve first line versus multiple lines of prior therapy can reveal differences in 
symptom occurrence and severity (Kaufman, 2015; Palmieri, 2015) although this can be 
somewhat deceiving given that many inclusion criteria for clinical trials requires that 
symptoms/toxicities are ≤ grade 1 or grade 2.   
Comorbidities.  Comorbidities may influence therapy-related symptom occurrence.  
Researchers showed that a higher number of comorbidities equated to more severe grades of 
graft versus host disease after patients (N = 2985) underwent hematopoietic cell transplantation 
(Sorror et al., 2014).  Specific to breast and gynecologic malignancies, Hamaker et al. (2014) 
found that in a sample of breast cancer patients 65 years of age and older, (N = 73) higher 
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numbers of comorbidities were significantly associated with grade 3 or 4 chemotherapy related 
toxicities including fatigue, mouth sores, and skin conditions.  An increased number of 
comorbidities was also a significant predictor of dose reductions of curative chemotherapy (due 
to toxicities) in a sample (N = 3707) of early stage breast cancer patients (Shayne, Crawford, 
Dale, Culakova, & Lyman, 2006).  Number of comorbidities was also significantly associated 
with greater symptom distress scores in a sample of cancer patients (N = 326) including 
gynecologic cancer diagnoses (Van Cleave, Egleston, Ercolano, & McCorkle, 2013).   
Health-Related Quality of Life (HRQOL) 
 In general, cancer patients experience decreased HRQOL, either due to the disease itself 
or due to the treatment modalities they endure (Yarbroff et al., 2007).  Clinical experience and 
numerous studies have confirmed the association between symptoms and HRQOL.  An increase 
in symptoms generally decreases HRQOL (Ferreira et al., 2008; Garrison, Overcash, & 
McMillan, 2011; Hyland & Sodergren, 1996; Janz et al., 2007; Miaskowski et al., 2006; 
Montazeri, 2008; Sloan, Cella, & Hays, 2005).  For instance, Montazeri (2008) conducted an 
extensive literature review that included 27 studies linking the impact of common symptoms of 
breast cancer patients such as fatigue, pain, and insomnia on quality of life.  The studies 
indicated that increased symptoms lowered patient’s QOL, particularly the symptom of fatigue 
(Montazeri, 2008).  Garrison et al. (2011) performed a secondary analysis to examine predictors 
of QOL in a sample of N = 533 adult patients with cancer receiving hospice care.  Findings 
showed that symptom occurrence, symptom severity, and functional status accounted for 46% of 
the variance in QOL (Garrison et al., 2011).   
 Many studies examining HRQOL concurrently measure symptoms given the overlapping 
nature of these two concepts.  For instance, Huang et al. (2013) also evaluated QOL along with 
symptoms.  Physical and mental QOL component scores were assessed using the 36-Item Short 
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Form Survey (SF-36).  While the physical component scores were significantly worse during 
therapy in all groups (chemotherapy alone, chemotherapy plus trastuzumab, and trastuzumab 
alone) compared to baseline, the mental component scores were significantly higher during the 
trastuzumab alone phase versus the chemotherapy alone phase (Huang et al., 2013).  Patients 
with higher symptom severity had worse physical and mental component scores regardless of the 
phase (Huang et al., 2013).   
 Williams et al. (2013) assessed whether the use of the TRSC with oncology outpatients 
receiving chemotherapy and/or radiation therapy increased the number of symptoms documented 
and managed and whether this improved patients' HRQOL.  Fifty-five oncology outpatients 
receiving either or both treatment modality received standard of care (group 1 [G1]).  At the 
same clinic, another cohort of 58 patients (group 2[G2]) received standard of care in addition to 
self-reporting symptoms on the TRSC prior to their clinical consultation.  This was a sequential 
cohort trial.  Repeated measures (2-11 visits) were obtained of the number of patient symptoms 
documented (medical records G1 and TRSC G2), HRQOL scores, and Karnofsky scores, for a 
total of 696 observations (328 G1 and 368 G2).  Results showed that a greater number of 
symptoms were identified and managed in G2 compared to the standard of care group (6.14 
symptoms vs. 2.84, P < .0001), and in G2, the number of symptoms declined by approximately 
1.5 every 100 days post-baseline more than in the standard of care cohort (Williams et al., 2013).  
 Janz et al. (2007) reported that sociodemographic, prior health status, clinical, and 
diagnosis factors accounted for 9% - 27% of the variance of QOL outcomes in breast cancer 
patients (N = 1372) that had completed surgery, chemotherapy, and/or radiation.  When 
symptoms related to the treatment of their cancer were added to the model, the percent of 
variance explained rose to 18% - 60%.  Ferreira et al. (2008) assessed HRQOL in 115 outpatients 
with cancer who were not receiving any type of treatment for their cancer.  Through cluster 
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analysis, the researchers found that patients with multiple and severe symptoms were four times 
as likely as those with lower symptoms/severity to have poor HRQOL (Ferreira et al., 2008).  
Smith et al. (2013) reported significantly worse HRQOL scores in young adults undergoing 
treatment of their cancer when they were experiencing ongoing symptoms.  Williams et al. 
(2011) conducted a Stetler model evidenced-based study to explore the effects of a nursing 
intervention on symptom management in 20 cancer patients that included 10 in the intervention 
group and 10 in the control group.  A two group repeated measures design was used.  In the 
intervention group, patient-reported symptoms on the TRSC were assessed and used as basis for 
education and counseling.  Outcomes were measured by the HRQOL-LASA scale and the 
Karnofsky performance/functional status scale and health form.  In the intervention group, 
patient education and counseling based on the TRSC, and nurse follow-up over time, were 
associated with a decrease in patient self- reported symptom occurrence and severity, and a trend 
that reflected improvement in HRQOL (Williams et al., 2011).   
 Including patient reported outcomes such as HRQOL is fundamental to understanding the 
patient’s experience in receiving treatment for their cancer, and over the past 20 years 
assessments of HRQOL have been increasingly included in cancer clinical trials.  While survival 
endpoints in cancer therapy clinical trials are predominant, HRQOL has been added to aid in the 
understanding of new therapies such as what additional survival means to patients (Bottomley et 
al., 2005).  This information may be useful to clinicians and patients when making therapy 
decisions.  For example, a phase III trial comparing different regimens of paclitaxel and 
carboplatin (both chemotherapies) for ovarian cancer found no statistically significant 
differences in terms of outcomes (Pignata et al., 2014), yet significant differences were found in 
terms of HRQOL between women who received weekly chemotherapy versus every three weeks.  
Unique to this trial, the researchers included QOL as a co-primary endpoint along with PFS.  In a 
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phase II trial that evaluated two different doses of interferon for the treatment of metastatic renal 
cell carcinoma, Tannir et al. (2006) found no significant differences in PFS and overall survival 
(OS) between the two treatment arms.  However, QOL was significantly better in the patients 
receiving the lower dose of interferon.  
 Perhaps one of the most innovative trials to date is the PISCES study, which used patient 
reported outcomes to help inform the choice of therapy in advanced metastatic renal cell 
carcinoma (RCC) (Escudier et al., 2014).  During this trial, 114 patients were randomly and 
blindly assigned to one of two approved targeted therapies for RCC - sunitinib and pazopanib.  It 
should be noted that these drugs are approved for RCC regardless of any genomic profiling 
results.  Therapy was switched after 10 weeks so that all patients were exposed to both drugs, 
and subsequently patients’ preferences and HRQOL were measured.  Findings showed that the 
patients preferred the pazopanib to sunitinib, reporting higher HRQOL scores (Escudier et al., 
2014).  Limitations included the attrition rate (33%) although this is not unexpected in a 
population with such advanced disease.  Also, patients’ preference and HRQOL were only 
assessed once during the trial and may not have captured the variations in the patients’ 
experience.   
 Studies specifically examining potential differences in HRQOL between patients who are 
receiving matched therapy and those who are not are lacking.  To date, there has been no study 
found in the literature specifically examining HRQOL in patients receiving therapy that has been 
selected based on genomic profiling results.  Given the changing paradigm of how cancer is 
being treated, this is an essential concept study in order to better understand how patients may be 






 Health-related quality of life is a measure of an individual’s perception of health-related 
well-being based on principle health components (Ferrans, Zerwic, Wilbur, & Larson, 2005) that 
typically include physical, emotional, mental, social and/or functional, and spiritual domains. 
Many tools are available to measure QOL and HRQOL.  In cancer clinical research trials, the 
European Organization for Research and Treatment of Cancer Quality of Life Questionnaire – 
Core 30 (EORTC QLQ-C30) and the Functional Assessment of Cancer Therapy-General 
(FACT-G) are often used.  Both questionnaires are self-reported measures and were specifically 
developed to assess the quality of life of cancer patients (EORTC Quality of Life, n.d.; 
FACIT.org, 2010).  The EORTC QLQ-C30 contains 30 items that address the physical, 
functional, social domains as well as specific questions regarding symptoms (EORTC Quality of 
Life, n.d.).  The FACT-G contains 27 items, which address the physical, social, emotional, and 
functional well-being domains (FACIT.org, 2010).   
 The EORTC QLQ-C30 and the FACT-G are lengthy and both have been criticized for the 
potential burden on patients, which may result in poor completion rates (Locke et al., 2007).  In a 
busy clinic setting, questionnaires that are short yet comprehensive, and easy to complete are 
desired elements.  The HRQOL-LASA was created and validated by Bretscher et al. (1999) for 
that purpose – to measure HRQOL with brief, multiple-item scales (Locke et al., 2007).  The 
HRQOL-LASA contains six items that cover the mental, social, spiritual, emotional, physical, 
and overall QOL domains.  Previous studies found a strong, inverse correlations between total 
HRQOL-LASA scores and total TRSC scores (Gonzalez et al., 2011; Heinze, 2012; Williams et 
al., 2013; Williams et al., 2011).  Studies conducted by Williams et al. (2011, 2012) showed that 
by using the TRSC, more symptoms were documented and thus managed, thereby increasing 




 The symptom experience of patients undergoing treatment for their cancer and 
corresponding impact on HRQOL has been reviewed.  Discussion included how cancer treatment 
is increasingly being personalized using genomic profililng.  This study will fill a gap in 
knowledge regarding the symptom experience and potential impact on HRQOL for patients 
undergoing matched therapy not previously explored.  Knowledge gained will not only inform 
nurses and other clinicians of possible sequelae of matched therapy but will also serve as a first 





 The purpose of this study was to describe the characteristics of patients with breast or 
gynecologic cancer undergoing matched therapy or not matched therapy, as well as to describe 
cancer therapy-related symptom occurrence and severity, and overall HRQOL for patients 
undergoing matched therapy and not matched therapy.  Associations between type of therapy 
(matched or not matched) and cancer therapy-related symptom occurrence and severity as well 
as HRQOL were examined after controlling for person and health/illness factors.  In this chapter, 
the design, study setting and sample are described and also the methodology that was used to 
collect and analyze the data.  
Research Design 
This study used a descriptive correlational research design to examine existing data on 
patients with either breast cancer or gynecologic cancer who are receiving care at a cancer center 
located in the upper Midwest.  A descriptive design was appropriate for this study because no 
studies have been found regarding symptom occurrence and severity and HRQOL for patients 
undergoing matched therapy.  This study examined the relationships among selected study 
variables, conceptually identified in the SMT.  Strengths of the descriptive correlational design 
included using existing data, which presents an inexpensive and cost-efficient opportunity to 
expand research opportunities that answer important research questions (Bullock, 2007; Vance, 
2012).  Using existing data are particularly useful for studying situations or events in real-life 






Study Setting and Sample 
 The study setting was a single-site, community, outpatient cancer center located in the 
upper Midwest.  This cancer center has the greatest volume of new breast and gynecologic 
cancer patients within a 200-mile radius.  Approximately 300 new breast cancer patients are seen 
each year, and roughly one-half of these patients require treatment with chemotherapy due to 
advanced or high-grade disease.  There are around 150 new gynecologic cancer patients seen 
each year.  Of these, about 70 will require therapy.  The cancer center routinely performs 
genomic profiling and uses these results to help match therapy decisions in appropriate cases as 
determined by the primary oncologists.  Approximately 450 patients with breast or gynecologic 
cancer received matched therapy from March 2014 to September 2016.  
 The sample for this study was derived from breast cancer patients who are enrolled in the 
ongoing research trial Using Metformin to Reduce Cardiac Toxicity in Breast Cancer Patients, 
and patients who are enrolled in the ongoing research trial Identifying Molecular Drivers of 
Cancer.  The purpose of the Using Metformin to Reduce Cardiac Toxicity in Breast Cancer 
Patients research trial is to determine if co-administration of metformin and doxorubicin 
(chemotherapy) in breast cancer patients who are receiving neoadjuvant or adjuvant therapy will 
reduce the number of patients who develop a significant change in left ventricle ejection fraction.  
This study began enrolling patients in August 2014.  The purpose of the Identifying Molecular 
Drivers of Cancer research trial is to identify mutational drivers of cancer by performing 
multiple molecular tests on the patient’s cancer tissue.  This study began enrolling patients in 
July 2015.  Enrollment and study procedures for both of these studies will continue until target 
enrollments are achieved (44 patients for Using Metformin to Reduce Cardiac Toxicity in Breast 
Cancer Patients; 1000 patients for Identifying Molecular Drivers of Cancer).   
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Criteria for inclusion in the current study were female patients that: (a) were enrolled in 
at least one of the parent studies, (b) have documented breast or gynecologic cancer, (c) were 
receiving cancer therapy that was either matched or not matched, and (d) who completed the 
TRSC and HRQOL-LASA questionnaire at least four weeks post initiation of the cancer therapy 
but no longer than 12 weeks after therapy began.  This time frame was chosen since cancer 
therapy-related symptoms and any potential impact on HRQOL may not be evident before four 
weeks.  Between four to 12 weeks, therapy-related symptoms and impact on HRQOL would be 
most evident.  After 12 weeks, symptoms typically stabilize and/or interventions have occurred 
that ameliorate symptoms and subsequent effects on HRQOL.  Additionally, staying within a 
range of four to 12 weeks was meant to minimize the variability and potential for significant 
differences between the groups that could be due to length of time on therapy.  Exclusion criteria 
included those patients: (a) not enrolled in either parent study, (b) for whom TRSC and HRQOL-
LASA were not gathered during the four to 12-week period post initiation of the matched or not 
matched therapy, or (c) missing TRSC and/or HRQOL-LASA data, or (d) for whom TRSC and 
HRQOL-LASA data were not gathered at the same time (e.g. TRSC gathered at four weeks post 
initiation of therapy and HRQOL-LASA gathered at five weeks post initiation of therapy).   
A	priori	Power	Analysis	for	Sampling	
 An appropriately powered study is essential for valid results.  A statistical power analysis 
involves the relationships among sample size, significance criterion (α), statistical power, and 
population effect size (Cohen, 1992).  An unadjusted comparison of groups based on a student’s 
t test at the 0.05 level of significance would require approximately 128 subjects to detect a 
medium effect (d = 0.5).  This study adjusted for several covariates (e.g., therapy type, age, 
length of therapy, prior lines of therapy, type and stage of disease, and comorbidities).  
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Considering all research questions, equations based on Cohen’s (as cited in Green, 1991) power 
analytic approach (N ≥ L/f2 where f2=R2/(1-R2) were used to estimate an adequate sample size.  
L = 6.4 + 1.65(m) – 0.05(m2) 
f2=R2/(1-R2) = .13/1-.13 = .15 
N ≥ 19/.15 = 127 subjects 
Assuming a medium effect size of R2  = 0.13, α = .05, m (independent variables) = 12, and 
desired power of 0.80 a total of 127 participants were estimated as sufficient.  Additionally, it 
was important to achieve relatively equal numbers of patients receiving matched therapy and 
patients receiving not matched therapy.     
Study Measures and Procedures 
 Study data included patient-reported information on cancer therapy-related symptoms 
occurrence and severity according to the TRSC, health-related quality of life according to the 
HRQOL-LASA, age and ethnicity (demographic data), and other measures including therapy 
type, concurrent therapy, length of therapy, prior lines of therapy, cancer type, cancer stage, and 
comorbidities.   
Therapy-Related Symptoms Checklist (TRSC) and Health-Related Quality of Life-Linear 
Analogue Self Assessment (HRQOL-LASA) Measures  
Therapy-Related Symptoms Checklist (TRSC).  Symptoms within the checklist are 
conceptually defined as “a subjective experience in the biopsychosocial functioning, sensations, 
or cognition of an individual” (Dodd et al., 2001, p. 669).  Measurement of symptom occurrence 
and severity were collected in the parent study Identifying Molecular Drivers of Cancer using the 
Therapy-Related Symptoms Checklist (TRSC).  Patients were asked to complete the TRSC each 
time they meet with the provider, which may vary based on the provider’s preference and on the 
patient’s regimen.  For example, the therapy may be administered every three or four weeks and 
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the provider meets with the patient prior to each administration.  Some oral chemotherapies or 
targeted agents were consumed daily.  Therefore, patients may be assessed every two to four 
weeks, depending on how often the provider deems necessary.    
 Measurement of symptom occurrence and severity in the parent study,	Using Metformin 
to Reduce Cardiac Toxicity in Breast Cancer Patients, were also collected using the TRSC.  
Patients were asked to complete the TRSC each time they meet with their provider, which is 
approximately every two to three weeks.  In both studies, trained research personnel give the 
paper form TRSC to the patients after they checked in to the clinic and while they are waiting to 
be seen by the provider.  Patients were instructed by the research personnel to check the 
symptoms they have experienced/are experiencing, and then circle the severity of the symptoms 
according to the scale provided.  The research personnel were available during the interval to 
answer questions.  Once completed, participants return the paper form to the research 
coordinator, which was then placed in a binder with other study-related documents.  
 The TRSC is a patient self-report instrument that subjectively measures cancer therapy-
related symptom severity (Williams et al., 1997; 2001).  Twenty-five physical and psychological 
symptoms commonly experienced during cancer therapy are included on the TRSC.  The 
severity of each symptom is rated by the patient using a 5-point scale ranging from 0 (not 
present) to 4 (severe) and scores are summated to reflect the total TRSC score.  A higher total 
score indicates higher symptom occurrence and severity as perceived by the patient (Williams et 
al., 1997; Williams et al, 2001).  Space exists at the bottom of the measure so that symptoms can 
be added if necessary, however, past studies have shown that fewer than 2% of patients have 
added symptoms (Piamjariyakul et al., 2010; Williams et al., 2001; Williams et al., 2006a; 
Williams et al., 2010a; 2010b; 2011; 2013; 2015).  The range of total scores is from 0-125 unless 
symptoms are added, in which case scores could theoretically exceed 125 (Appendix C).    
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Good psychometric properties have been reported for the TRSC in previous studies 
across a variety of settings (Gonzalez, Williams, Tirado, & Williams, 2011; Heinze, 2012; 
Piamjariyakul et al., 2010; Williams et al., 2001; Williams et al., 2006a; Williams, Williams, & 
Doolittle, 2006b; Williams et al., 2010a; 2010b).  Cronbach’s alpha, which measures internal 
consistency, has been reported as ranging from 0.70 to 0.83 or higher in prior studies using the 
paper format (Gonzalez et al., 2011; Piamjariyakul et al., 2010; Williams et al., 2001; Williams 
et al., 2006a; 2006b; Williams et al., 2010a; 2010b; Williams et al., 2011; Williams et al., 2013; 
Williams et al., 2015a).  Construct validity and discriminant validity (up to 80% correctly 
classified) have been shown in adult patients receiving chemotherapy versus radiation therapy 
(Williams et al., 2001) and various populations within and outside the USA (Gonzalez et al., 
2011; Heinze, 2012; 2014; Piamjariyakul et al., 2010; Mische-Lawson et al., 2012; Williams et 
al., 2010a; 2010b; 2014).  Its use also has been tested in a cancer center health care delivery 
system and shown to impact HRQOL, number of symptoms identified and managed, and 
functional status (Williams et al., 2011; 2013).  
 In the current study, data on each TRSC response item and extra responses were 
extracted from the paper form completed by each patient.  Some patients in the parent study 
completed the TRSC more than once during their course of cancer therapy.  To minimize 
variation, TRSCs completed within a four to 12-week timeframe from the start of the current 
therapy were used.  Meaning, for matched therapy, the first TRSC completed during the four to 
12-week time period after beginning matched therapy was extracted and used in the analysis.  
For not matched therapy, the first TRSC completed during the four to 12-week time period after 
beginning not matched therapy was extracted and used in the analysis.  The time of TRSC 
completion since the initiation of the cancer therapy was recorded in weeks. 
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Health-Related Quality of Life-Linear Analogue Self Assessment (HRQOL-LASA). 
Health-related quality of life is a measure of an individual’s perception of health-related well-
being based on principle health components (Ferrans, Zerwic, Wilbur, & Larson, 2005) including 
the physical, emotional, mental, social, spiritual, and overall QOL (Bretscher et al., 1999).  
Measurement of HRQOL is collected in both parent studies using the Health-Related Quality of 
Life-Linear Analogue Self-Assessment (HRQOL-LASA) tool.  For the parent studies, the 
HRQOL-LASAs were collected at the same time points as the TRSCs.  While patients waited to 
see their provider, trained research personnel provided the paper form HRQOL-LASA with 
instructions for completion.  Once the patients completed the form, they returned it to the 
research personnel, which was then placed in the patient’s research binder.   
The HRQOL-LASA is a six-item questionnaire that represents overall QOL and overall 
physical, emotional, mental, social, and spiritual wellbeing (one item for each component).  Each 
item is self-rated on a 10-point scale from 0 (as bad as it can be) to 10 (as good as it can be).  
When item scores are summated, total scores can range from 0-60 (Appendix D).  A high score 
on the HRQOL-LASA indicates a high quality of life.   
 The HRQOL-LASA was initially validated in patients with cancer receiving hospice care 
(Bretscher 1999).  Also, items within the questionnaire have been validated as general measures 
of global QOL dimensional constructs in multiple settings (Grunberg, Groshe, Steingass, 
Zaretsky, & Meyerowicz, 1996; Gudex, Dolan, Kind, & Williams, 1996; Hyland & Sodergren, 
1996).  Cronbach’s alpha, a measure of the scale’s internal consistency, has recently been 
reported as 0.83 in a study of patients with brain cancer (Locke et al., 2007), and 0.93 in a study 
of breast cancer patients who had completed primary treatment with surgery, radiation therapy, 
and/or chemotherapy (Heinze, 2012).  The HRQOL-LASA has been used in numerous studies 
that also use the TRSC.  Strong, inverse correlations (r = -0.29 to -0.47) between scores on the 
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HRQOL-LASA and total TRSC scores have been reported showing construct and discriminant 
validity (Gonzalez et al., 2011; Heinze, 2012; Williams et al., 2013; Williams et al., 2011).       
 For the current study, HRQOL-LASA item scores as well as the total score were 
extracted from the patient paper forms and entered into the dataset.  Some patients in the study 
completed the HRQOL-LASA more than once during their course of cancer therapy.  To 
minimize variation, data from the first HRQOL-LASA completed during the four to 12-week 
time period from the start of the current therapy (matched or not matched) were extracted and 
used in the analysis.  The time of HRQOL-LASA completion since the initiation of the cancer 
therapy was recorded in weeks. 
Other Measures for the Proposed Study 
 Demographic data.  Demographic data on patient age and ethnicity were obtained to 
appropriately describe the sample characteristics in the research report.  Typically, demographic 
data including patient birthdate, age, and ethnicity, are recorded in the patient’s electronic health 
record (EHR) when the patient is admitted to the service.  Age was defined as age in years when 
the patients completed the TRSC and HRQOL-LASA; the date the TRSC and HRQOL-LASA 
were completed is recorded on each form.  For this study, data on age and ethnicity were 
extracted from the EHR and/or the patient’s study binder (from either parent study) and entered 
into the dataset by the investigator.  Data on ethnicity was used to describe the sample.    
 Socioeconomic data.  Socioeconomic data on patient health insurance type and drug 
coverage were obtained to describe the sample characteristics.  Health insurance type 
conceptually referred to third party coverage for the individual’s health/illness related expenses.  
Operationally health insurance type was defined as no insurance/self-pay, Medicare, Medicaid, 
or commercial insurance.  Commercial insurance was any private insurance that the patient paid 
for, or shared in the cost of with their employer.  Drug coverage was conceptually defined as 
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how the costs of a patient’s cancer drugs (therapies) were covered.  Operationally, drug coverage 
was defined as health insurance, samples, patient assistance programs, self-pay, or a combination 
of these possibilities.  For this study, data on health insurance type and drug coverage were 
extracted from the EHR and/or the patient’s study binder (from either parent study) and entered 
into the dataset by the investigator.   
Family cancer history.  Family cancer history referred to whether or not the patient had 
relatives that had been diagnosed with cancer.  Operationally this variable was categorized as 
family history of breast cancer, gynecological cancer, any cancer, or none.  Data on family 
cancer history were extracted from the EHR and entered into the dataset by the investigator 
during this study.  These data were used to describe the sample. 
Therapy type. Therapy type referred to matched therapy or not matched therapy. 
Conceptually, matched therapy was defined as matching a specific cancer therapy or therapies 
that is/are known to target a genomic alteration(s) to the patient’s genomic alteration(s), which 
is/are found on genomic profiling.  For this study, matched therapy was operationally defined as 
the use of at least one drug that is known to target the genomic alteration of at least one of the 
patient’s genomic alterations found on genomic profile testing.   
Conceptually not matched therapy referred to therapy or therapies used to treat cancer 
that is/are not matched to specific genomic alteration(s).  For this study, not matched therapy was 
operationally defined as the use of drugs that were not specifically matched to the patient’s 
genomic alterations.  Patients receiving not matched therapy may or may not have had genomic 
profile testing.  If a patient had undergone genomic profile testing, several factors may have 
influenced whether or not they received matched therapy.  One factor is that 10% to 15% of the 
time, a genomic alteration is found on testing that does not have a drug that will target it.  If this 
occurred, patients would receive not matched therapy only.  Another factor influencing type of 
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therapy is insurance coverage.  Many cancer therapies are very expensive and may not be 
approved for the type of cancer it is being requested.  For example, an ovarian tumor may exhibit 
an alteration that is commonly seen in breast cancer.  Even if a therapy specifically targeting that 
alteration is FDA approved for breast cancer, many insurances will not allow a patient with 
ovarian cancer to obtain this drug.  If the drug(s) was/were not obtained through insurance or 
other means (i.e. patient assistance programs, self-pay), then patients would receive not matched 
therapy.  Patients receiving not matched therapy who did not undergo genomic profile testing, 
may or may not have received other testing on their cancer, and may have received or be 
receiving a drug that targets a pathway in tumor growth (e.g. testing for hormone status [ER/PR] 
in breast cancer).  
 The investigator searched the patient record to extract information on therapy type, which 
was readily available since information regarding therapy type is not blinded in the parent study. 
Therapy type was operationally defined as the type of therapy being received at the time the first 
TRSC and HRQOL-LASA were completed during the four to 12-week time period after the start 
of the current therapy.  Documenting the therapy type patients received when completing the 
questionnaires was important since patients may change regimens upon progression of disease, 
or if they are unable to tolerate the therapies (e.g. allergic to therapy, intolerable side effects).  
For verification purposes, a random reassessment of 20% of patients was performed. 
At the outpatient cancer center, genomic profiling is performed with the FoundationOne 
assay which uses the Illumina HiSeq 2000 platform for next generation sequencing.  The 
FoundationOne assay indicates a patient’s particular cancer genomic profile, and from these 
findings, recommendations can be made based on therapies available to match the specific 
alterations found.  Briefly, DNA is first extracted from cancer tissue that is taken from routine 
biopsy or surgical specimens.  Then, the extracted DNA’s entire coding sequence of over 4,500 
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exons of 315 cancer-related genes is interrogated, in addition to approximately 50 introns 
(segments of a DNA or RNA molecule that does not code for proteins but interrupts the sequence 
of genes [Intron, n.d.]) from 28 genes that are often altered in cancer.  Results of the 
FoundtionOne assay are available in 14-21 days (FoundationOne, 2014; Framptom et al., 2013).  
Most types of genomic alterations are detected with the FoundationOne assay, which include: a) 
Base substitutions, where one base is exchanged for another (i.e. an A switching to a G); b) 
Indels, which refers to insertions – when extra base pairs are inserted into a new place in the 
DNA, or deletions – when a section of DNA is lost; c) Copy number alterations, which refers to 
an abnormal variation in the number of copies in one or more sections of the DNA; and d) 
Rearrangements, which refers to a change in the structure of the native gene and includes 
selected gene fusions.  Validation of the assay was completed in several ways, which was 
necessary given the different alteration types being detected.  Validation of the assay included 
creating pools of normal cell lines as well as tumor cell lines to model key determinants of 
accuracy including allele frequency, indel length, and amplitude of copy change.  Concordance 
between the FoundationOne assay and a variety of current clinical technologies was examined, 
such as HER2 FISH testing,  (Frampton et al., 2013).  Reproducibility was validated by 
examining specimens independently.  Results showed that this assay reports high sensitivity (≥ 
90%) and specificity (≥ 99%) (FoundationOne, 2014; Frampton et al., 2013).  Table 3 provides 
information regarding the validity of the FoundationOne assay. 
Table 3 
Sensitivity, Specificity, and Positive Predictive Value (PPV) of the FoundationOne Assay 
 Base Substitutions Indels Copy Number 
Alterations 
Rearrangements 
Sensitivity > 99% > 97% > 95% ≥ 90% 
 
Specificity > 99% > 99% > 99% > 99% 
 
PPV > 99% > 99% > 99% > 99% 
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 Concurrent therapy.  Concurrent therapy referred to the specific information regarding 
all types of therapy the patient was receiving at the time the TRSC and HRQOL-LASA 
questionnaires were completed (surgery, chemotherapy, radiation therapy, and targeted therapy).  
Patients with metastatic cancer may have been receiving matched therapy based on their 
genomic alterations, but may have also received chemotherapy depending on the context.  For 
instance, many agents targeting genomic alterations are cytostatic, therefore, in the case of an 
aggressive tumor, it may be best to add chemotherapy (which is cytotoxic).  The patient’s overall 
clinical situation is also incorporated into the decision of recommended therapy.  If patients do 
not have metastatic disease, they will receive chemotherapy according to established guidelines 
plus or minus matched therapy based on their genomic alterations.  For example, a breast cancer 
patient receiving neoadjuvant therapy may receive chemotherapy plus a matched therapy for 12 
weeks prior to receiving surgery.  A patient with gynecologic cancer (non-metastatic) may have 
surgery first, followed by chemotherapy plus a matched therapy based on the genomic 
alterations.  The type of therapy (surgery, chemotherapy, radiation therapy, and targeted therapy) 
was extracted from the EHR to the study dataset by the investigator.    
 Length of therapy.  Length of therapy conceptually referred to the amount of time in 
weeks a patient had been on the current therapy (matched or not matched) when the TRSC and 
HRQOL-LASA were completed (see earlier discussion of TRSC and HRQOL-LASA completion 
time points).  Length of therapy was operationally defined as the number of weeks that patients 
were receiving the designated therapy at the time the TRSC and HRQOL-LASA were 
administered.  The research investigator calculated this based on the number of days from the 
start of therapy date as recorded in the EHR, and the date on which the TRSC and HRQOL-
LASA were administered. 
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 Prior lines of therapy.  Conceptually, prior lines of therapy referred to the number of 
regimens a patient received to treat their cancer prior to the therapy upon which therapy type was 
determined (matched or not matched).  Regimens for different treatment modalities, specifically 
chemotherapy, are generally changed in response to disease progression or due to lack of 
tolerability.  Prior lines of therapy were operationally defined as the number of regimens the 
patient received prior to the therapy received during the administration of the TRSC and 
HRQOL-LASA.  Data on prior lines of therapy were retrieved from the patient’s record by the 
research investigator.  Additionally, the type of therapy received in prior lines (i.e. surgery – type 
of procedure; radiation - anatomical location, chemotherapy and/or targeted therapy – specific 
drug) was extracted from the EHR to the dataset.   
  Cancer type and stage.  Cancer type is defined by the tissue or organ where the cancer 
originated from (NCI, 2015b) and in this study was categorized as breast cancer or gynecologic 
cancer.  Cancer type is entered in the EHR by the treating oncologist upon diagnosis.  Cancer 
type was determined from the EHR for this study after verifying the diagnosis on pathology 
reports in the patients’ EHR.   
 Cancer stage describes the severity of the cancer, which is based on the location, size, and 
extent of the primary cancer tumor (AJCC, 2015).  The primary oncologist determines the cancer 
stage at diagnosis, which is entered into the patient’s EHR.  For the current study, the stage of 
the cancer (stage 1, 2, 3, or 4), was obtained from the EHR.  Additionally, information regarding 
whether the disease was metastatic or not was obtained from the EHR and recorded in the study 
dataset.  Metastatic disease was confirmed by pathology or radiological reports showing that the 
primary site of cancer (e.g. breast, gynecologic) had spread to other tissues or organs in the body 
(NCI, n.d.a).   
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 Comorbidities.  Comorbidities are the presence of one or more additional diseases 
occurring with the primary disease (cancer) (Comorbidity, 2009).  Operationally, comorbidities 
were defined as patient diagnoses other than cancer as defined by the International Classification 
of Diseases, 10th Revision, Clinical Modification (ICD-10-CM) diagnosis code (ICD-10-CM 
Official Guidelines for Coding and Reporting, 2016).  Existing data of study patient 
comorbidities including ICD-10 code and descriptor were extracted from the EHR and recorded 
for each patient in the study dataset.  The number of categories per patient were used in the 
regression analyses.   
Ethical Considerations 
 No study-related procedures occurred until the study was fully reviewed and approved by 
the Avera Oncology Institutional Review Board (IRB).  Since the study was being conducted at 
Avera, the University of Kansas Medical Center’s IRB reviewed and agreed to rely on Avera 
IRB approval of the study.  A Memorandum of Understanding was signed between the two 
institutions, which established an agreement for the designation of IRB responsibilities.  The 
study investigator had access to patient electronic health care records in the clinic.  The study 
variables were recorded in an excel spreadsheet, which was contained on the password protected 
Q-drive at the cancer center.  Participants were given a unique de-identifiable numeric code on 
the spreadsheet.  Once all variables were recorded, patient identifying information including 
patient name was removed and the excel file was transferred to the study investigator’s 
password-protected personal computer.  The file linking patient name to the de-identifiable 
numeric code is maintained on the password protected Q-drive of the cancer center.  Study-
related paper forms for this study will be destroyed after the study has ended.  The data file will 
be maintained in a secured file for a minimum of seven years, which is the requirement of 
KUMC’s IRB.  This is longer than what is required from Avera’s Oncology IRB, whose policy 
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requires data to be maintained on site for three years, followed by three years off site (total of six 
years).  Any publications from the study will not contain participant identifiers; results will be 
reported in aggregate.  The study investigator has maintained Health Insurance Portability and 
Accountability Act (HIPAA) and human protection subjects training.    
Data Analysis 
Data Preparation and Management 
The research investigator was responsible for extracting the necessary data for this study 
as well as maintaining the data in an excel spreadsheet.  The research investigator maintained a 
log of any analytic decisions as well as a codebook, which contained demographic and other 
study variables with corresponding level of measurement.  The codebook also included recoding 
decisions that occurred during the course of the study.  
Data for the study were collected from May 2016 to September 2016.  Intra-rater 
reliability of the extracted data was established by re-extracting data from a random 10% of the 
patients with the exception of the therapy type variable, on which a random reassessment of 20% 
of the patients was performed.  The audit of therapy type revealed 100% agreement.  Intra-rater 
reliability of the remaining variables was 85%.  Most of the disagreement occurred in 
comorbidity and family cancer history data and was due to EHR anomalies.  For instance, 
comorbidities were typically included in progress notes, but were frequently not recorded as 
comorbidities or other diagnoses per ICD-10 in the EHR.  Additionally, comorbidities listed by 
the clinician in the progress notes varied based on the patient’s changing condition (e.g. 
development of a GI ulcer).  Furthermore, the outpatient cancer center site uses a different EHR 
than the hospital, which required looking for data in two different EHRs for accuracy.  The 
decision was made to record family cancer history and comorbidities that were listed in at least 
one of the EHRs at the time closest to when the questionnaires were completed.  After the first 
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audit, comorbidities and family cancer histories were reviewed and updated if necessary for each 
subject, referencing both EHRs.  A random reassessment on comorbidities and family cancer 
history for 20% of the patients revealed 100% agreement.  The data were reviewed for outliers 
and if any values appeared to be extreme, they were re-checked against the EHR, TRSC, and/or 
HRQOL-LASA.  There were no missing data.   
In order to prepare the data for analysis, categorical and ordinal data were recoded as 
appropriate.  For example, data on ethnicity yielded an initial four categories.  These data were 
recoded into three groups: Caucasian, Hispanic, and Asian/Native American.  Insurance type was 
recoded as no insurance/self-pay, Medicare, Medicaid, or commercial.  Drug coverage was 
recoded as health insurance, samples, patient assistance programs, or a combination of health 
insurance/samples, health insurance/patient assistance, samples/patient assistance, or 
insurance/samples/patient assistance.  Data recorded for family history of cancer was coded as 
yes or no for breast cancer, gynecologic cancer, and other cancer.  Concurrent therapy type was 
recoded as yes or no for chemotherapy, targeted therapy, or a combination of 
chemotherapy/targeted therapy.  The type of prior therapy was also recoded as yes or no under 
the following treatment modality categories: Surgery, radiation, chemotherapy, or targeted 
therapy.  The number of treatment modality categories was then summed for each patient.  Data 
recorded for metastatic disease were recoded as yes or no.  For each patient, the ICD-10 codes 
were grouped by ICM-10-CM category (ICD-10-CM Official Guidelines for Coding and 
Reporting, 2016).  The comorbidities were recoded as yes or no for each corresponding ICD-10-
CM code (ICD-10-CM Official Guidelines for Coding and Reporting, 2016).  The number of 
categories were then counted to obtain the total number of comorbidities for the patient. 
A number of decisions were made during the data preparation phase.  For the variable 
“number of prior lines of therapy”, each therapy and/or different treatment modality was counted 
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as a line.  For example, the treatment plan for a patient with breast cancer receiving neoadjuvant 
therapy may include chemotherapy, surgery, radiation therapy and targeted therapy.  For this 
study, each of these modalities was counted as a line of therapy due to the nature of therapy- 
related symptoms compounding each other.  Also, the investigator discovered that several 
patients, who were being treated for gynecologic cancer, had previously been treated for breast 
cancer.  In these instances, therapies received for their breast cancer were counted as a prior line 
of therapy.   
A potentially important variable, previously not recognized, emerged during the data 
preparation and analysis phase.  It was noted that the timing of the most recent prior line of 
therapy was not being accounted for, but that this conceptually could influence patient symptom 
occurrence and severity and/or HRQOL.  For example, a prior line of therapy for one patient 
may have been months or even years ago, while a prior line of therapy for another patient may 
have been weeks ago.  Since a large portion of the symptoms on the TRSC are a result of acute 
sequelae from therapy, patients whose prior therapy occurred shortly before their current therapy 
(e.g. within three months) may not have had complete resolution of these acute symptoms.  
Therefore, the decision was made to include the timing of the prior line of therapy as a variable 
for description in research question #1, and a control variable in the regression model for 
research questions #3 and #4.  For those patients that had undergone prior therapy for their 
cancer, this variable was conceptually defined as the timing of the most immediate prior therapy.  
Operationally the timing of the prior line of therapy was extracted from the EHR and categorized 
in the dataset as immediate (zero to less than three months), three months (three months to less 
than one year), and one year or greater.  These categories were chosen based on the anticipated 
differences in symptom occurrence and severity at the different time points.  For instance, acute 
symptoms from therapy such as nausea and vomiting would be expected to resolve shortly 
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(within weeks) after therapy completion, while certain symptoms such as fatigue may persist six 
months or more past therapy completion.  Study power was recalculated (equations based on 
Cohen’s as cited in Green, 1991) to confirm adequate sample size with the additional variable. 
L = 6.4 + 1.65(m) – 0.05(m2) 
f2=R2/(1-R2) = .13/1-.13 = .15 
N ≥ 19.4/.15 = 129 subjects 
Assuming a medium effect size of R2 = 0.13, α = .05, m (independent variables) = 13, and 
desired power of 0.80 a total of 129 participants were estimated as sufficient.  Other decisions 
made during the data preparation phase included noting that some patients in the sample were 
diagnosed with bilateral, simultaneous breast cancers that were different stages.  For this study, 
the breast cancer with the highest stage was recorded in the dataset, since the therapy plan would 
be based on the higher stage.  Finally, the number of days for the length of current therapy 
variable, as calculated from the start of therapy date recorded in the EHR, and the date on which 
the TRSC and HRQOL-LASA were administered, was rounded up or down to weeks.  For 
example, if the patient had been on therapy for six weeks and five days, then the number of 
weeks recorded in the dataset was seven weeks.  Once the dataset was recoded, reviewed, and 
complete, it was uploaded to SPSS version 22 (IBM Corp. SPSS, Armonk, NY, USA).  All 
analyses were performed in SPSS. 
Data analysis for research question #1.  The first research question for the study was: 
What are the characteristics (demographic data, socioeconomic data, length of therapy, 
concurrent therapy, prior lines of therapy [number, type, and timing], cancer type and stage, 
and number of comorbidities) of patients by type of therapy (matched therapy, not matched 
therapy)?  Descriptive statistics were used to summarize the characteristics of the patients by the 
type of therapy.  Categorical and ordinal data (ethnicity, insurance type, drug coverage, family 
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cancer history, concurrent therapy, prior treatment modalities, cancer type, cancer stage, and 
timing of prior line of therapy) were reported as frequencies and distributions.  Results for 
continuous variables (age, length of therapy, prior lines of therapy, comorbidities) were reported 
as a mean and standard deviation. 
Data analysis for research question #2.  The second research question was as follows: 
What is the occurrence and severity of cancer therapy-related symptoms as reported on the 
Therapy-Related Symptom Checklist (TRSC) and overall HRQOL as reported on the Health-
Related Quality of Life – Linear Analogue Self Assessment (HRQOL-LASA) for patients 
receiving matched therapy and those receiving not matched therapy?  Descriptive statistics were 
used to report the TRSC and HRQOL-LASA individual item scores and total scores for patients 
receiving matched and not matched therapy.  The TRSC total score was obtained by summating 
the 25 symptom severity scores, and the HRQOL-LASA total score was obtained by summating 
the score of the six items.  Both the TRSC total score and HRQOL-LASA total score were 
reported as a mean and standard deviation.  The frequency and distribution of TRSC and 
HRQOL-LASA item scores were also reported.    
Symptoms added to the TRSC by patients were evaluated for appropriate placement in 
existing categories.  For instance, several patients added “nosebleed” to the list of symptoms 
instead of selecting “bleeding” from the existing TRSC items.  Therefore, the investigator 
reclassified “nosebleed” as “bleeding” on the TRSC and moved the intensity rating for 
“nosebleed” to the TRSC item “bleeding.”  Similarly, two patients rated the “pain” item as zero, 
but added “feet tenderness” and “aches” to the list of symptoms.  In both cases, the investigator 
reclassified “feet tenderness” and “aches” as “pain” on the TRSC and moved the intensity ratings 
for “feet tenderness” and “aches” to the TRSC item “pain”.  “Blurry vision” and “vision 
changes” were added to the list of symptoms by two patients, and, in this case, the investigator 
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reclassified these as “other - vision changes”.  One patient claimed the TRSC item symptom 
“skin changes,” and rated the intensity of this symptom as “four””  The patient also added 
“rash,” “skin peeling”, and “cracked heels” to the list of symptoms.  Since these were in addition 
to the “skin changes” item, the investigator decided to keep these as separate symptoms.  They 
were reclassified as “other - rash,” “other - skin peeling”, and “other - cracked heels”.  In further 
instances, “loose BM” was reclassified as “other - diarrhea”, while “toe nail” was reclassified as 
“other - nail changes”.  One patient added “diarrhea” to the list of symptoms but did not rate the 
severity, therefore the severity was left blank.  Two other symptoms – “right side upper hip” and 
“toe” – were added to the list of symptoms but were unclear as to what they were referencing.  
Therefore they were reclassified as “other – right side upper hip,” and “other – toe”.  Altogether, 
21 symptoms were added.     
Evaluation of the scale’s reliability was accomplished by performing the Cronbach’s 
alpha, which evaluates the consistency with which a measure assigns scores to subjects, and the 
extent to which the measure leads to similar results regardless of the variations that may occur 
(internal consistency) (Ferketich, 1990).  A Cronbach’s alpha was performed on the original 25-
item TRSC as well as the six-item HRQOL-LASA.  Additionally, a Cronbach’s alpha was run on 
the TRSC with the added “Other” item scores.  
Multiple Linear Regression Analysis 
  Data analysis for research question #3.  The third research question was: What is the 
association between type of therapy (matched therapy versus not matched therapy) and overall 
occurrence and severity of cancer therapy-related symptoms as reported on the TRSC after 
controlling for person (age) and health/illness factors (cancer type, cancer stage, length of 
therapy, number of prior lines of therapy, timing of prior line of therapy, and number of 
comorbidities)?  Symptom occurrence and severity as reported on the TRSC was the dependent 
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variable for this research question.  The total TRSC score was used, which was summated from 
the original 25 TRSC items.  To examine the association between therapy type and symptoms, a 
multiple linear regression model was built.  Multiple linear regression is used when the 
dependent variable is measured with a continuous (interval or ratio) level measure (Institution for 
Digital Research and Education, 2017; Sousa, 2010), as is the case in the current study.  
 First, procedures to examine model assumptions were conducted and included normality 
testing, evaluation of potential multicollinearity, and assessing independence of the data.  The 
continuous data were evaluated for normality by reviewing histograms, Q-Q plots, skew, and 
kurtosis values.  Indices for acceptable values of skewness and kurtosis were set at -2 to +2 
(Field, 2013).  Values for skewness in this study ranged from -0.27 to 0.96 and values for 
kurtosis ranged from 0.98 to 0.41 indicating sufficient normal distribution.  Correlations between 
variables were evaluated and generally ranged from 0.003 to 0.48.  The highest correlation of 
0.55 was between cancer stage 3 and cancer type (see Table 4).  However, variance inflation 
factors (VIF) values for all variables were less than 10 (range 1.1 to 3.04) and tolerance values 
for all variables were greater than .10 (range 0.33 to 0.90) indicating little multicollinearity 
(Mendenhall & Sincich, 2012; Sousa, 2010).  Independence of observations was checked by the 
Durbin-Watson statistic (Sousa, 2010).  In this study and for this analysis, the Durbin-Watson 










After assessing the model assumptions, a multiple linear regression analysis was performed.  The 
independent variable, therapy type, was modeled using a categorical indicator variable (x = 0 for 
not matched therapy, x = 1 for matched therapy) and included covariates age, cancer type and 
stage, length of therapy in weeks, number of prior lines of therapy, timing of prior line of 
therapy, and number of comorbidity categories.  Table 5 shows the variables that were included 
in the regression model.  Three dummy variables were created for the variable cancer stage 
(stage 2, stage 3, stage 4) with stage 1 as the reference variable, and three dummy variables were 
created for the variable prior line of therapy timing (< 3 months, > 3months but < 1 year, > 1 
year), with no prior therapy as the reference variable.   
Table 5 
Variables for Research Question #3 
 
Independent variable Dependent variable 
Therapy type (categorical) Symptom occurrence/severity (TRSC scores – 
continuous) 
Control variables Type of data 
Age Continuous 
Cancer type Categorical 
Cancer stage Categorical 
Length of therapy Continuous  
Prior lines of therapy Continuous 
Timing of prior line of therapy Categorical 
Comorbidities Continuous 
 Note. TRSC = Therapy-Related Symptom Checklist 
 Independent variables were entered into the model by step.  In the first step, therapy type 
was added.  The remaining independent variables were added to the model in the second step. 
Two-tailed significance tests (F-test) for each step in the model were performed and reported.  
Additionally, the t-value and corresponding probability (p)-value, as well as the unstandardized 
B, and the standard error of the estimate (SE) for each variable were determined and reported.  
Level of significance was set at alpha ≤ 0.05.  
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 Data analysis for research question #4.  The fourth research question was: What is the 
association between type of therapy (matched therapy versus not matched therapy) and overall 
HRQOL as reported on the HRQOL-LASA after controlling for person (age) and health/illness 
factors (cancer type, cancer stage, length of therapy, number of prior lines of therapy, number of 
comorbidities, and overall symptom occurrence and severity)?  Health-related quality of life was 
the dependent variable for this research question as defined by the total HRQOL-LASA, which 
was summated from individual item scores.  To examine the association between therapy type 
and HRQOL, a multiple linear regression model was built. 
 Procedures to examine model assumptions were conducted first, and included normality 
testing, evaluation of potential multicollinearity, and assessing independence of the data.  The 
continuous data were evaluated for normality by reviewing histograms, Q-Q plots, skew, and 
kurtosis values.  Indices for acceptable values of skewness and kurtosis were set at -2 to +2 
(Field, 2013).  Values for skewness ranged from -0.70 to 0.962, and values for kurtosis ranged 
from 0.98 to 0.41, indicating sufficient normal distribution.  Correlations between variables were 
evaluated and generally ranged from 0.002 to 0.48.  The highest correlation of 0.55 was between 
cancer stage 3 and cancer type (see Table 6).  However, variance inflation factors (VIF) values 
for all variables were less than 10 (range 1.1 to 3.1) and tolerance values for all variables were 
greater than 0.10 (range 0.32 to 0.90) indicating little concern for multicollinearity (Mendenhall 
& Sincich, 2012; Sousa, 2010).  Independence of observations was checked by the Durbin-
Watson statistic (Sousa, 2010).  In this study and for this analysis, the Durbin-Watson statistic 







After assessing the model assumptions, a multiple linear regression analysis was 
performed.  The independent variable, therapy type, was modeled using a categorical indicator 
variable (x = 0 for not matched therapy, x = 1 for matched therapy), and included covariates age, 
type and stage of disease, length of therapy, prior lines of therapy, timing of prior line of therapy, 
comorbidities, and symptoms (TRSC scores).  Table 7 shows the variables that were included in 
the regression model.  The three dummy variables created for the variable cancer stage (stage 2, 
stage 3, stage 4) with stage 1 as the reference variable and the three dummy variables created for 
the variable prior line of therapy timing (< 3 months, > 3months but < 1 year, > 1 year) with no 
prior therapy as the reference variable were also used in the analysis. 
Table 7 
Variables for Research Question #4 
Independent variable Dependent variable 
Therapy type (categorical) HRQOL (HRQOL-LASA scores – continuous) 
Control variables Type of data 
Age Continuous 
Cancer type Categorical 
Cancer stage Categorical 
Length of therapy Continuous  
Prior lines of therapy Continuous 
Timing of prior line of therapy Categorical 
Comorbidities Continuous 
Symptoms (TRSC scores) Continuous 
 Note. HRQOL-LASA = Health-Related Quality of Life – Linear Analogue Self Assessment, TRSC = Therapy-
Related Symptom Checklist;  
  
Independent variables were entered into the model by step. After careful consideration, it 
was decided to enter the variables in three steps instead of the previously planned two step model 
to better characterize the contribution of the TRSC score.  In the first step, therapy type was 
added.  The variables age, cancer type, cancer stage, length of therapy, prior lines of therapy, 
timing of prior line of therapy, and number of comorbidities were added in the second step.  
Symptoms (TRSC scores) were added in the final step.  Two-tailed significance tests (F-test) for 
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each step in the model were performed and reported.  Additionally, the t-value and 
corresponding p-value, as well as the unstandardized B, and SE for each variable were 
determined and reported; level of significance was also set at ≤ 0.05.   
Summary 
 This chapter presented an overview of the methods used to analyze symptom occurrence 
and severity as well as HRQOL in patients with breast or gynecologic cancer receiving matched 
or not matched therapy.  These analyses of existing data are the first known for this population, 
and will provide a better understanding of the association between the type of therapy (matched 
or not matched) and symptom experience and HRQOL.  This study utilizes descriptive and 
multiple linear regression statistical methods to answer the questions proposed.  Chapter Four 








This chapter presents the findings of the analyses performed on existing data of breast 
and gynecologic cancer patients to assess symptom occurrence and HRQOL among those 
receiving matched or not matched therapy.  Specifically, the following results will be discussed: 
a) The characteristics of the study sample by type of therapy, b) Symptom occurrence and 
severity and HRQOL by type of therapy, c) The association between type of therapy and overall 
symptom occurrence and severity as reported on the TRSC while controlling for person and 
health/illness factors, and d) The association between type of therapy and HRQOL as reported on 
the HRQOL-LASA after controlling for person and health/illness factors.    
Description of Study Sample 
 The final study sample was comprised of 129 female patients.  The overwhelming 
majority of the sample was Caucasian (n = 124, 96%), and their mean age was 56 years (SD = 
10.8).  Among the study women, 73% (n = 94) had a diagnosis of breast cancer while 27% (n = 
35) had a diagnosis of gynecologic cancer.  Only 15% (n = 19) patients in the sample reported no 
family history of cancer.  Among those that did have a family history of cancer, 80 patients 
(62%) had more than one family member with a cancer history.  Fifty-four percent (n = 70) were 
considered to have metastatic disease at the time of this study, and most of the patients in the 
sample (n = 102, 79%) had undergone prior cancer therapy for their cancer diagnosis.  Of the 
patients who had had prior cancer therapy, the mean number of prior lines of therapy was 3.3 
(SD = 3.2), and the most frequent prior treatment modalities were surgery (n = 79, 61%) and 
chemotherapy (n = 81, 63%).  All but one patient had health insurance of some type; most 
patients had commercial insurance (n = 88, 68%), and most of their drug coverage was provided 
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by health insurance (n = 102, 79%).  The mean length of current therapy for the entire sample 
was 7.2 weeks (SD = 2.3).     
Research Question #1 
Among the sample, 67 patients (52%) received matched therapy and 62 patients (48%) 
did not receive matched therapy.  The demographic and clinical profiles of the patients receiving 
matched and not matched therapy in this study are shown in Table 8.  Patients receiving matched 
therapy were slightly older on average (57 years, SD = 12.1) than those patients receiving not 
matched therapy (55 years, SD = 13.4).  The ethnicity of both groups was mainly Caucasian.  
Although the majority of patients had commercial insurance and drug coverage was largely 
provided by the patients’ insurances, more patients receiving matched therapy required 
additional assistance for drug coverage in the form of drug samples and/or patient assistance 
programs compared to those not receiving matched therapy.  The percentage of patients with a 
family history of cancer was nearly equal between groups.   
 Most patients receiving matched therapy were receiving a combination of chemotherapy 
and targeted therapy representing a total of 55% (n = 37).  Patients may have received more than 
one targeted therapy concomitantly, and the combination of therapies for patients receiving 
matched therapy varied.  Table 9 shows the compiled list of targeted therapies used to target the 
genomic alteration(s) among patients receiving matched therapy.  Eight of the 15 targeted 
therapies listed are currently approved by the FDA for the treatment of cancer types other than 
breast or gynecologic cancer, including renal cell cancer, melanoma, lung cancer, leukemia, and 
prostate cancer.  Only two of the 15 targeted therapies listed (temsirolimus, olaparib) are 
currently approved by the FDA for the treatment of gynecologic cancer, and six of the 15 
(everolimus, palbociclib, lapatinib, pertuzumab, trastuzumab, TDM1) are currently approved by 








Targeted Therapies Used for Patients Receiving Matched Therapy 
List of Targeted Therapies 
 


















Pembrolizumab (immunotherapy) 4 
Note. TDM1 = ado-trastuzumab emtansine  
a Total of no. of patients receiving each targeted therapy exceeds the sample size of patients receiving matched 
therapy since many patients received more than one type of targeted therapy. 
 
Most patients receiving not matched therapy were receiving chemotherapy only (63%).  
Mean length of current therapy for patients receiving matched therapy was 6.8 weeks (SD = 2.3) 
compared to 7.6 weeks (SD = 2.3) for patients receiving not matched therapy.  Patients receiving 
matched therapy had more prior lines of therapy on average (M = 4.3, SD = 3.2) compared to 
patients receiving not matched therapy (M = 2.2, SD = 2.9).  Thirty nine percent (n = 24) of 
patients receiving not matched therapy had no prior line of therapy compared to just 5% (n = 3) 
of the patients receiving matched therapy.  The number of different types of treatment modalities 
used in the prior lines of therapy (surgery, radiation, chemotherapy, or targeted therapy) were 
higher for patients receiving matched therapy (M = 2.5, SD = 1.2) compared to patients receiving 
not matched therapy (M = 1.4, SD = 1.4).  The mean number of comorbidities was slightly higher 
for patients receiving matched therapy (M = 2.2, SD = 1.5) compared to patients receiving not 
matched therapy (M = 2.0, SD = 1.6).  Endocrine diseases were the most common comorbidity 
for patients receiving matched therapy (n = 28, 42%) while circulatory diseases were the most 
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frequent comorbidity for patients receiving not matched therapy (n = 25, 40%).  See Table 10 for 
the distribution of comorbid conditions among the sample by therapy type.  
Note, ICD-10 = International Statistical Classification of Diseases – 10th revision.       




The rate of breast and gynecologic cancers were evenly distributed between patients 
receiving matched therapy and patients receiving not matched therapy.  By stage, there were 
more stage 3 cancers in patients receiving not matched therapy (n = 22, 36%) than patients 
receiving matched therapy (n = 17, 25%).  Conversely there were more stage 4 cancers in 
patients receiving matched therapy (n = 30, 45%) than in patients receiving not matched therapy 
(n = 12, 19%).  
Research Question #2 
Therapy-Related Symptom Checklist (TRSC) Scores 
The mean number of symptoms reported on the original 25-item TRSC across all 129 
subjects was 8.2 (SD = 4.9).  Patients receiving matched therapy reported a mean number of 8.0 
symptoms (SD = 4.9), and patients receiving not matched therapy reported a mean number of 8.4 
symptoms (SD = 5.2).  In regard to overall symptom occurrence and severity, the mean total 
TRSC score for the patients receiving matched therapy was 14.7 (SD = 10.1), which was lower 
than the mean total TRSC score for patients receiving not matched therapy (M = 16.1, SD = 
11.6).   
Table 11 shows the count (frequency of occurrence) of each symptom, the mean rating of 
severity for each symptom, and the rank of occurrence by therapy type on the original 25-item 






The symptom with the highest occurrence as reported by patients receiving matched and 
not matched therapy was “feeling sluggish.”  Most of the other symptoms were reported at 
similar rates of occurrences, with the following exceptions: a) “numbness in fingers and/or toes” 
was the second highest occurring symptom as reported by patients receiving matched therapy, 
compared to the eighth highest occurring symptom as reported by patients receiving not matched 
therapy; b) “pain” was the fourth highest occurring symptom as reported by patients receiving 
matched therapy compared to the 11th as reported by patients receiving not matched therapy; c) 
“difficulty concentrating” was the ninth highest occurring symptom as reported by patients 
receiving matched therapy compared to the third as reported by patients receiving not matched 
therapy; and, d) “hair loss,” which was the 10th highest occurring symptom as reported by 
patients receiving matched therapy compared to, again, the third as reported by patients receiving 
not matched therapy.    
Evaluation of the severity of each item on the original 25-item TRSC revealed that eight 
symptoms had higher mean severity ratings for patients receiving matched therapy compared to 
patients receiving not matched therapy.  The eight higher mean severity ratings included the 
following symptoms: “sore mouth”, “jaw pain”, “shortness of breath”, “pain”, “numbness in 
fingers and/or toes”, “bleeding”, “skin changes”, and “soreness in vein”.  Of these eight 
symptoms, “pain” was notably higher in terms of both occurrence and severity for patients 




Figure 2.  Occurrence and severity of pain on the TRSC as self-reported by patients receiving 
matched therapy or not matched therapy. 
 
Patients receiving matched therapy had higher occurrence but slightly lower mean 
severity ratings for six other symptoms when compared to patients receiving not matched 
therapy, and included the following: “feeling sluggish”, “difficulty sleeping”, “weight loss”, 
“fever”, “bruising”, and “cough”.  The remaining symptoms on the 25-item TRSC had higher 
occurrence and/or mean severity ratings for patients receiving not matched therapy.  Of these, 
“hair loss” was notably higher in terms of occurrence and severity for patients receiving not 
matched therapy compared to the patients receiving matched therapy (see Figure 3).  The overall 




Figure 3. Occurrence and severity of hair loss on the TRSC as self-reported by patients receiving 
matched therapy or not matched therapy. 
 
 Fourteen (25%) of the patients receiving matched therapy added symptoms to the TRSC 
and 23 (37%) of the patients receiving not matched therapy added symptoms to the TRSC (see 
Table 12).  In all, 37 patients (29%) added symptoms to the TRSC, which is much higher relative 
to past TRSC studies where less than 2% of patients added symptoms to the TRSC (Williams et 
al., 2013).  Consequently, mean total TRSC scores by therapy type that included the additional 
symptoms were also calculated.  For patients receiving matched therapy the mean TRSC score 
with the added symptoms was 15.2 (SD = 10.5), which was lower than the mean TRSC score for 
patients receiving not matched therapy (M = 17.0, SD = 12). When the added symptoms were 
included in the analysis, the overall Cronbach’s alpha value was 0.81.   
81 
 






Health-Related Quality of Life – Linear Analogue Self Assessment (HRQOL-LASA) Scores   
 Overall, patients rated their HRQOL relatively high, with a combined mean total 
HRQOL-LASA score of 46.8 (SD = 8.4).  The mean total HRQOL-LASA score for patients 
receiving matched therapy was 48.1 (SD = 7.5) which was higher than the mean score of 45.4 for 
patients receiving not matched therapy (SD = 9.1).  The Cronbach’s alpha for the HRQOL-
LASA was 0.89.  
 Evaluation of the individual HRQOL-LASA item responses revealed that ratings on the 
overall QOL item ranged from three to 10 for patients receiving matched therapy and for patients 
receiving not matched therapy.  The distribution of ratings for this item is shown in Figure 4.  
The mean score for overall QOL was slightly higher for patients receiving matched therapy (M = 
7.93, SD = 1.57) versus patients receiving not matched therapy (M = 7.53, SD = 1.73). 
 
Figure 4.  Perception of overall QOL as reported by patients receiving matched therapy or not 




Ratings on the mental well-being item ranged from five to 10 for patients receiving 
matched therapy, compared to a range of four to 10 for patients receiving not matched therapy.  
The distribution of ratings for overall mental health well-being by therapy type is shown in 
Figure 5.  The mean score for overall mental well-being was higher for patients receiving 
matched therapy (M = 8.28, SD = 1.25) compared to patients receiving not matched therapy (M = 
7.95, SD = 1.52).   
 
Figure 5. Perception of overall mental well-being as reported by patients receiving matched 
therapy or not matched therapy. 
 
Ratings on the overall physical well-being item ranged from four to 10 for patients 
receiving matched therapy compared to a range of two to 10 for patients receiving not matched 
therapy.  The distribution of ratings for overall physical well-being is shown in Figure 6.  The 
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mean score for overall physical well-being for patients receiving matched therapy was slightly 
higher (M = 7.33, SD = 1.78) than patients receiving not matched therapy (M = 7.26, SD = 1.78).   
 
Figure 6.  Perception of overall physical well-being as reported by patients receiving matched 
therapy or not matched therapy. 
 
 Ratings on the overall emotional well-being item ranged from four to 10 for patients 
receiving matched therapy compared to a range of three to 10 for patients receiving not matched 
therapy.  The distribution of ratings for overall emotional well-being is shown in Figure 7.  The 
mean score for overall emotional well-being was higher for patients receiving matched therapy 
(M = 7.97, SD = 1.42) compared to patients receiving not matched therapy (M = 7.61, SD = 




Figure 7.  Perception of overall emotional well-being as reported by patients receiving matched 
therapy or not matched therapy. 
  
Ratings on the level of social activity item for patients receiving matched therapy ranged 
from zero to 10 compared to a range of two to 10 for patients receiving not matched therapy.  
The distribution of ratings for level of social activity is shown in Figure 8.  The mean score for 
level of social activity for patients receiving matched therapy was notably higher (M = 7.85, SD 




Figure 8. Perception of level of social activity as reported by patients receiving matched therapy 
or not matched therapy. 
 
Finally, ratings on the overall spiritual well-being item ranged from zero to ten for 
patients receiving matched therapy compared to a range of one to 10 for patients receiving not 
matched therapy.  The distribution of ratings for overall spiritual well-being is shown in Figure 
9.  The mean score for overall spiritual well-being was higher for patients receiving matched 
therapy (M = 8.63, SD = 1.76) compared to patients receiving not matched therapy (M = 8.23, 




Figure 9. Perception of overall spiritual well-being as reported by patients receiving matched 
therapy or not matched therapy.    
 
Research Question #3. 
Multiple linear regression modeling to determine the relationship between study variables 
and total TRSC scores (Table 13) revealed that less than 1% of the variance in symptom 
occurrence and severity was explained by therapy type alone (matched versus not matched), ∆ R2 




















About 10.3% of the variance in symptom occurrence and severity was explained by the 
linear combination of all the variables in the model (e.g., therapy type [matched versus not 
matched], age, cancer type, cancer stage, length of therapy in weeks, number of prior lines of 
therapy, timing of prior lines of therapy, and number of comorbidities), ∆ R2 = 0.10, ∆ F = 1.2, p 
= 0.35, which was not statistically significant.    
Type of therapy (matched therapy versus not matched therapy) was not significantly 
associated with the total TRSC scores after controlling for person (age) and health/illness factors 
(cancer type, cancer stage, length of therapy, number of prior lines of therapy, timing of prior 
line of therapy, and number of comorbidities).  Patients who had prior therapy less than three 
months before the onset of the current therapy type had a significantly higher TRSC total score 
relative to patients with no prior therapy (B = 6.2, p = 0.045) after controlling for all other 
variables in the model.  The remaining variables – cancer type, cancer stage, length of therapy, 
number of prior lines of therapy, and number of comorbidities – were not significantly associated 
with a higher or lower TRSC total score.  
Research Question #4 
Multiple linear regression modeling to determine the relationship between study variables 
and total HRQOL-LASA scores (Table 14) revealed that 3% percent of the variance in HRQOL 
was explained by therapy type (matched versus not matched), ∆ R2 = 0.03, ∆ F = 3.6, p = 0.06, 









An additional 11% of the variance in HRQOL was explained by the addition of age, cancer type, 
cancer stage, length of current therapy, timing of prior line of therapy, number of lines of prior 
therapy, and comorbidities to the model, ∆ R2 = 0.11, ∆ F = 1.3, p = 0.137, which was not 
statistically significant.  After adding total TRSC scores to the model, 33% of the variance in 
HRQOL was explained by the linear combination of all the variables in the model (e.g. therapy 
type [matched versus not matched], age, cancer type, cancer stage, length of current therapy, 
number of lines of prior therapy, timing of prior line of therapy, number of comorbidities, and 
total TRSC score).  Twenty percent of the variance in HRQOL was explained by the TRSC score 
alone,  ∆ R2 = 0.20, ∆ F = 33.6, p = < 0.001, which was statistically significant.   
Patients who had a higher number of prior lines of therapy had significantly higher 
HRQOL-LASA scores (B = 0.56, p = 0.05) after controlling for all other variables in the model.  
Patients who had higher TRSC scores had significantly lower HRQOL-LASA scores (B = -
0.361, p = < 0.001) after controlling for all other variables in the model.  The remaining study 
variables – age, cancer type, cancer stage, length of therapy, timing of prior line of therapy, and 
comorbidities – were not significantly associated with a higher or lower HRQOL-LASA total 
score.  
Summary 
This chapter has presented the results of this descriptive correlational study using existing 
data.  The results of the first and second research questions addressed the descriptive data of the 
sample characteristics and specific questionnaire-related data by therapy type respectively.  The 
results of the third and fourth research questions addressed the associations between type of 
therapy and symptom occurrence and severity and HRQOL respectively, while controlling for 
relevant variables.  Chapter Five will discuss the results as well as their implications for practice, 




Discussion, Conclusions, and Recommendations 
This chapter discusses findings relevant to the study and how the results contribute to the 
knowledge of the symptom experience and HRQOL in patients receiving matched cancer 
therapy.  The study examined the characteristics of patients with breast or gynecologic cancer 
receiving matched or not matched therapy, their symptom occurrence and severity and HRQOL, 
as well as associations between type of therapy, symptoms, HRQOL, and person and 
health/illness factors.  Implications for practice and theory will be addressed as well as 
unanswered questions that are suitable for future research questions.     
Significance of the Study 
This study is believed to be the first to describe symptom severity and occurrence and 
HRQOL in patients who received matched therapy and not matched therapy, and to investigate 
potential associations among person and health/illness factors.  Matched cancer therapy as a 
treatment option for cancer is becoming more common due to the increased availability of 
genomic profiling in the clinical setting.  Patients and clinicians alike desire information about 
the symptoms associated with matched therapy, their potential severity, and their impact on 
HRQOL.  The study aligns with national research objectives set forth by the NINR, Healthy 
People 2020, and the NCI to advance the science of symptoms and QOL in the context of 
chronic diseases and precision medicine (Grady & Gough, 2015; Healthy People, 2015; NINR, 
n.d.; 2016; Reeve et al., 2014).       
Discussion of the Results 
Characteristics of Patients by Type of Therapy 
 The sample of patients in this study was overwhelmingly Caucasian, presumably because 
the setting was South Dakota where Caucasians represent 86% of the state population (United 
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States Census Bureau, 2015).  The mean age for the entire sample (matched and not matched) 
was 56 years (SD = 10.8), which is comparable to the age of participants in studies examining 
matched therapy in terms of progression free survival (PFS) (Schwaederle 2015, Andre et al., 
2014), but lower than national statistics indicating an average age of 60 years for patients with 
breast and gynecologic cancers (Howlander et al., 2016).  However, patients receiving matched 
therapy in this study were slightly older on average compared to the patients receiving not 
matched therapy.  This is in contrast to the study by Tsimberidou and colleagues (2014) in which 
patients receiving matched therapy were proportionately younger compared to patients receiving 
not matched therapy.  
The sample was representative of the patients served at the Cancer Center in which the 
study was conducted.  Breast cancer patients comprised a majority of the sample, which is 
reflective of the higher number of breast cancer patients seen at the study site as well as of the 
higher incidence of breast cancers compared to gynecologic cancers (ACS, 2015).  Most of the 
patients in this study had commercial insurance, a finding that is reflective of the mean age of the 
sample, assuming many switch to Medicare at age 65.  Nevertheless, 37% of the patients 
receiving matched therapy required assistance in addition to their insurance to obtain their drugs 
compared to just 2% of patients receiving not matched therapy.  The finding is understandable 
given the increased likelihood of drug(s) being prescribed for patients with a type of cancer other 
than what the drug was originally approved for.  This is often referred to as off-label use, which 
is common in matched therapy as indicated by the list of targeted therapies used in this study 
(Table 9), most of which are currently approved for cancers other than breast and gynecologic 
cancer.  Currently, for a drug to be approved by the FDA it must have a disease indication (e.g. 
breast cancer).  Even if the drug approved was developed to target a specific alteration that is 
seen in a variety of different cancers, that drug will still only be approved in a specific type or 
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types of cancer.  Although the FDA does not control provider decisions about which drugs 
should be prescribed for their patients, insurance companies including Medicare frequently deny 
coverage of the drug(s) when it/they are used off label.  As a result, the lack of insurance 
coverage for off-label use is a major barrier in the implementation of matched therapy.  Even if 
insurance companies approve the (off-label) use of the matched therapy, Medicare and other 
insurances have placed many of these targeted cancer therapies on “specialty tiers”, which 
requires payments that are 20% to 40% or more of the drug cost regardless of their income 
(Balch, 2015).  As an example, the drug everolimus costs approximately $10,000 per month.  
Patients would thus be required to pay $2000 to $4000 for a one month supply, rendering the 
therapy virtually inaccessible for most without additional assistance outside of patients’ 
insurance.  Various foundations in the form of non-profit organizations and patient assistance 
programs through the pharmaceutical companies exist to assist patients with drug acquisition 
and/or co-pay help (Association of Community Cancer Centers [ACCC], 2017).  However, many 
organizations will only provide financial assistance if the drug being requested is approved for 
use in the type of cancer in which it is FDA approved.  The need to address these barriers and 
improve access to drugs is currently being discussed among national organizations like the 
American Society of Clinical Oncology, and is part of the Cancer Moonshot SM agenda (NCI, 
2016a). 
  The majority of patients in the study had a family history of cancer.  The NCI (2016b) 
estimates that nearly 40% of men and women will experience a diagnosis of cancer at some point 
during their lifetime, yet familial patterns of cancers due to inherited genetic alterations 
(germline alterations) comprise just 5% - 10% of these cancers (NCI, 2015e).  A majority of 
cancers, therefore are due to somatic alterations.  Interestingly, there were several study patients 
with an extensive family history of breast, gynecologic, and/or other cancer(s), suggesting a 
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pattern of potential germline alterations.  Although these patients were referred for genetic 
counseling during their care, studies have found that cancer patients who meet the criteria for 
genetic counseling (e.g. extensive family history, young age at diagnosis) are often not referred 
for genetic testing despite the current guidelines and known importance of this counseling 
(Meyer et al., 2010; Murff, Byren, & Syngal, 2004; Wood et al., 2014).  Even when a patient has 
already developed cancer, genetic testing is still critical since a germline alteration may suggest 
that a certain therapy will be beneficial for the patient.  Additionally, other family members may 
be at risk of developing cancer and should be given the opportunity to learn about potential risk 
mitigation strategies.   
 All patients receiving matched therapy were receiving targeted therapy, which are listed 
in Table 9.  The patients in this study were not co-enrolled to phase I clinical trials because they 
were receiving targeted therapy/therapies that were already FDA approved for treatment of some 
type of cancer.  In contrast, previous studies examining matched therapy were phase I or phase II 
clinical trials testing targeted therapies that were not yet FDA approved (Andre et al., 2014; 
Schwaederle et al., 2015; Tsimberidou et al., 2012; 2014).  About half (51%) of the patients in 
this study were receiving chemotherapy in addition to the targeted therapy, which is similar to 
other studies comparing matched and not matched therapy (Schwaederle et al., 2015; 
Tsimberidou et al., 2012; 2014).  
Patients receiving matched therapy had received nearly twice as many prior lines of 
therapy compared to patients receiving not matched therapy.  Studies by Andre et al. (2014) and 
Tsimeridou (2012; 2014) also showed that patients receiving matched therapy had higher 
numbers of prior lines of therapy.  More than likely, these patients have tried traditional cancer 
therapies that failed, and were willing to try novel therapies (Rubin, 2015).  Conversely, patients 
receiving not matched therapy were more likely than patients receiving matched therapy to have 
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no prior therapy.  This may be because criteria for inclusion in one of the parent studies (Using 
Metformin to Reduce Cardiac Toxicity in Breast Cancer Patients) was a history of zero to one 
prior line of therapy.  Also, patients who have never received therapy before are expected to 
receive traditional therapies before receiving matched therapy.  Before any new cancer 
therapy/therapies becomes part of usual care, data must indicate that the therapy/therapies are 
safe and superior to the usual care.  It is typical that new therapies are trialed in patients with 
more advanced disease.  It was therefore not unanticipated that there were more patients with 
stage 3 disease receiving not matched therapy and more patients with stage 4 disease that were 
receiving matched therapy.  
 In this study, patients receiving matched therapy had more comorbidities than patients 
receiving not matched therapy.  Previous studies have found that patients with more advanced 
cancer and who have lived with cancer for longer periods of time have an increase in 
comorbidities (Ah et al., 2015; Land, Dalton, Joregensen, & Ewertz, 2012; Morice, Leary, 
Creutzberg, Abu-Rustum, & Darai, 2016; Patnaik, Byers, DiGuiseppi, & Dabelea, 2011; Urban 
et al., 2016), but these studies were not conducted within the context of matched therapy.  This 
study found that circulatory diseases and endocrine diseases were the most frequently reported 
comorbidities, which was also found in other studies of patients with breast and gynecologic 
cancers (Land et al., 2012; Siegelmann-Daneili et al., 2006; Shah et al., 2014).  Known 
relationships between circulatory diseases and in particular breast cancer exist due to breast 
cancer therapy-related cardiotoxicities from certain chemotherapies (e.g. anthracyclines), 
radiation therapy, and targeted therapies (e.g. trastuzumab) (Vo, Nolan, Vance, Patrician, & 
Meneses, 2017).  Relationships between gynecologic and breast cancers and 
hyperglycemia/hyperinsulinemia have been proposed but not fully characterized (Shah et al., 
2014; Sun et al., 2016; Vrachnis et al., 2016).     
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Symptom Occurrence and Severity 
Therapy-Related Symptom Checklist (TRSC) scores.  This study found that cancer 
therapy is associated with a variety of adverse symptoms, which is consistent with prior study 
reports (Chen & Tseng, 2006; Janz et al., 2007; Kenne-Sarenmalm et al., 2007; Kirkova et al., 
2011; Lopez, et al., 2015; Miller-Reilly et al., 2013; Reeve et al., 2014).  In this study, the 
average number of symptoms reported across the sample was eight (M = 8.2), which was 
essentially equal to the average number of symptoms experienced by patients receiving matched 
therapy (M = 8.0), and not matched therapy (M = 8.4).  Results are similar to those by Janz et al. 
(2007) who found the average number of symptoms reported in a sample of breast cancer 
patients that had recently completed cancer therapy was seven.  Likewise, Chen and Tseng 
(2006) reported that the average number of symptoms among patients with a variety of cancers 
receiving chemotherapy was seven, while Williams et al. (2015a) found the average number of 
symptoms reported by a sample of patients with different cancer types receiving chemotherapy 
and/or radiation therapy to be eight.  It is noted that, like this study, Williams et al. (2015a) used 
the TRSC for symptom occurrence and severity assessment in a cross-sectional manner.  Other 
studies have found that patients receiving chemotherapy and/or radiation therapy reported a 
higher number of symptoms.  Spichiger et al. (2011) and Keene-Sarenmalm et al. (2007)  found 
the average number of symptoms to be 14.  
Symptom occurrence as reported on the TRSC for this study was similar to that found in 
past studies using the TRSC (Lopez et al., 2015; Piamjarijakul et al., 2010; Williams et al, 
2010a; Williams et al., 2001; Williams et al., 2013; Williams et al., 2010b; Williams et al., 
2015a; Williams et al., 2006a; Williams et al., 1997; Williams et al., 2011).  For example, the 
following symptoms—“taste change”, “loss of appetite”, “nausea”, “numbness in fingers and/or 
toes”, “feeling sluggish”, and “difficulty sleeping”, were symptoms with high reports of 
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occurrence by patients receiving matched and not matched therapy in this study, as was the case 
in the Williams et al. (2010a) and Williams et al., (2015a) studies.  The symptom with the 
highest occurrence as reported by patients receiving matched and not matched therapy was 
“feeling sluggish.”  Results parallel those from Williams et al. (2010a), Williams et al. (2015a), 
and Williams et al. (2006a) that also found “feeling sluggish” was the most frequently reported 
symptom.   
In this study, there was little difference in symptom occurrence and/or severity between 
patients receiving matched or not matched therapy except for “numbness in fingers and/or toes”, 
“difficulty concentrating”, “pain”, and “hair loss”.  For patients receiving matched therapy, the 
second highest occurring symptom was “numbness in fingers and/or toes”.  It is noted that these 
patients also had a higher number of prior lines of therapy compared to patients receiving not 
matched therapy.  This is consistent with findings by Lewis et al. (2015), who reported that 
patients who had received chemotherapy in prior lines of therapy had significantly higher levels 
of neuropathy (Lewis et al., 2015).  Many of the patients receiving matched therapy in this study 
were currently receiving or had previously received chemotherapy for their cancer, and many of 
these agents are known to cause nerve damage (Majithia, Loprinzi, & Smith, 2016).   
The occurrence of the symptom “difficulty concentrating” was higher for patients 
receiving not matched therapy, which was interesting since patients receiving matched therapy 
had a higher number of prior lines of therapy on average.  Cognitive impairments such as 
difficulty concentrating, thinking, and/or memory problems are commonly experienced by 
patients undergoing cancer therapy (ACS, 2016).  The cause of cognitive impairment in cancer 
patients is likely multifactorial, and prior studies have found links between cognitive impairment 
and specific chemotherapies (Majithia et al., 2016), anxiety, and depression (Janelsins et al., 
2016).  It may be that patients receiving not matched therapy in this study were more anxious 
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about their treatment given less experience with cancer therapy (2.2 previous lines of therapy on 
average), and thus experienced more difficulty concentrating.   
Pain occurrence was higher for patients receiving matched therapy as was its severity.  
This is perhaps because more patients receiving matched therapy had stage 4 disease, and 
patients with metastatic disease (where the primary site of cancer has spread to other tissues or 
organs in the body) frequently experience pain (Gilbertson-White et al., 2011; Kim, Dodd, 
Aouizerat, Jahan, & Miaskowski, 2009; Reeve et al., 2014).  Hair loss occurrence was higher for 
patients receiving not matched therapy as was its severity, which was related to the higher 
number of these patients that were receiving chemotherapy.  Hair loss is a known side effect of 
certain chemotherapies, particularly the types of chemotherapies used to treat breast and 
gynecologic cancers.  
  Higher TRSC scores correspond to higher symptom occurrence and severity, and in this 
study, total TRSC scores reported for the 25-item TRSC were 14.7 on average for patients 
receiving matched therapy, and 16.1 on average for patients receiving not matched therapy.  The 
average TRSC score for patients receiving not matched therapy is similar to findings by 
Williams et al. (2011) in which patients receiving chemotherapy showed a mean TRSC score of 
16.5.  Other studies using the TRSC found the mean TRSC scores to be slightly higher compared 
to mean TRSC scores in this study (Piamjarijakul et al., 2010; Williams et al., 2010b).  
Piamjarijakul and colleagues (2010) found that the mean TRSC score was 17.9 among a sample 
of cancer patients in Thailand who were receiving chemotherapy, while Williams and colleagues 
(2010b) found that the mean TRSC score was 17.7 among a sample of cancer patients in China 
who were receiving chemotherapy.  It is again noted that prior studies using the TRSC were 
conducted in samples of patients who were receiving not matched therapy.  The higher TRSC 
scores found in the Piamjarijakul et al. (2010) and Williams et al. (2010b) studies could 
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substantiate prior research showing that Asian women receiving chemotherapy report greater 
side effects (Bordeanu et al., 2012; Ma, Yeo, Hui, Wing, & Johnson, 2002). Higher TRSC scores 
may also be related to differences in supportive care measures in other countries compared to the 
United States.  Nonetheless, the average TRSC scores for patients receiving matched therapy in 
this study were lower compared to previous studies of patients receiving not matched therapy 
(Piamjarijakul et al., 2010; Williams et al., 2010b; Williams et al., 2011).  
In this study, patients receiving matched therapy had a higher number of prior lines of 
therapy on average and a higher occurrence of stage 4 disease.  These patients had lower TRSC 
scores, which conflicts with previously reported findings that patients who have received 
multiple lines of therapy, and/or have advanced stages of cancer have higher symptom burdens 
(Boland et al., 2013; Kaufman, 2015; Kirkova et al., 2011; Lewis et al., 2015; Palmieri, 2015; 
Walsh et al., 2000).  Potentially, this could be because many of the patients had tried traditional 
therapies, failed, and were running short on further treatment options.  These patients may under-
report symptoms out of fear that they will be taken off a potentially life-extending therapy, and 
although clinicians admit concern about this based on the investigator’s experience, there is no 
existing data to support this concern.  Results may also be because patients receiving matched 
therapy had prior cancer therapy-related symptom experience as indicated by a higher number of 
stage 4 cancers (more advanced disease) and a higher mean number of prior lines of therapy.  
Consequently, the patients and/or their clinicians may have become more proficient at managing 
symptoms over time.  This is supported by the findings of Williams et al. (2011) in a study 
conducted among a sample of patients receiving chemotherapy and/or radiation therapy who 
completed the TRSC at three time points: baseline, approximately three weeks after starting 
therapy, and approximately six weeks after starting therapy.  After an initial rise in mean TRSC 
scores at the second time point (compared to baseline), mean TRSC scores decreased at the third 
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time point.  Stabilization or improvement of symptoms over time is congruent with findings by 
other investigators including Dujit et al. (2011), Given et al. (2002); Visser et al. (2000), and 
Williams et al. (2013), but is in contrast to Spichiger et al., (2011), who found that compared to 
baseline, symptoms of patients receiving chemotherapy significantly increased when assessed 
two and three months after the start of chemotherapy.  These divergent results may be related to 
the interventions performed to alleviate the symptoms in the studies showing symptom 
improvement over time (Dujit et al, 2011; Given et al. 2002; Williams et al., 2013).  For this 
study, the assessment of symptoms in both groups occurred at similar time points to each other 
(6.8 weeks for patients receiving matched therapy versus 7.6 weeks for patients receiving not 
matched therapy), which is comparable to the second and third time points of symptom 
assessments in the Spichiger et al. (2011) and Williams et al. (2011) studies respectively.  Since 
symptom assessments were not performed longitudinally in this study, it is unknown whether 
symptoms had initially worsened and improved over time, or became more severe over time after 
the start of matched or not matched therapy.  
The TRSC was developed in 1997 and much has changed in cancer care over the past 20 
years.  Although many symptom items are still relevant to today’s therapies, several items were 
not frequently experienced including “jaw pain” (6%), “fever” (9%), and “soreness in vein where 
chemotherapy was given” (10%).  Jaw pain is a potential side effect of a small number of 
chemotherapies; chemotherapies that are not used to treat breast or gynecologic cancers.  
Soreness in the vein where the chemotherapy is administered also may have less relevance than 
previously since most patients have central venous lines for infusions versus peripheral 
intravenous catheters.  Also, many contemporary cancer therapies are taken orally.  Future 
studies should determine the relevance of these items in a broader cancer population.   
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A substantial number of patients added symptoms to the TRSC compared to prior studies, 
suggesting the TRSC may not fully capture the symptoms related to newer treatment modalities. 
In all, 21 patients added symptoms to the TRSC, and surprisingly more patients receiving not 
matched therapy added symptoms compared to patients receiving matched therapy.  This could 
be because many patients receiving not matched therapy had less experience with cancer 
treatment and were therefore motivated to report their symptoms in greater detail.  All patients, 
regardless of the type of therapy they received, knew that they were in a research study and were 
fully informed of the therapies they were receiving for their treatment regimen.  This may have 
led to the patients’ increased motivation for reporting detailed symptom information, since they 
were aware that researchers were seeking this information.   
The mean TRSC score with the added symptoms was lower for patients receiving 
matched therapy compared to patients receiving not matched therapy.  This was unexpected 
since patients receiving matched therapy were receiving novel combinations of therapy.  Results 
may suggest that symptoms are not significantly different between matched or not matched 
therapy, or results may suggest that symptoms are not fully captured on the TRSC.  Diarrhea was 
the most common symptom added for both groups.  Other studies using the TRSC also reported 
the addition of diarrhea (Williams et al.2010; Williams et al., 2015a), which suggests it is a 
symptom that should be considered for inclusion in a revised version of the TRSC.  This addition 
is supported by the work previously described by Miller-Reilly (2013) and Reeve et al. (2014), in 
which diarrhea was identified as one of 12 core symptoms that should be assessed in oncology 
clinical trials.  Skin changes was another symptom frequently added by participants in this study.  
Conceptually, the added symptoms: “rash”, “peeling skin”, and “nail changes”, could be 
collapsed under skin changes.  Providing a descriptor for each TRSC symptom or allowing space 
along side of each existing symptoms for patients to add their variation of the TRSC symptom 
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would be beneficial.  In this study, several added symptoms had unclear meanings such as “toe,” 
or “right upper hip.”  It would have been helpful if the meaning of these added symptoms items 
were clarified in real time with the patient, at which time a descriptor could be added, or the item 
correctly classified.  It is worth noting that several symptoms added by the patients were 
objective side effects rather than subjective, including “neutropenia” and “delayed wound 
healing.”  The patient reporting neutropenia was reporting an objective toxicity of the therapy, 
but she was not experiencing the symptom of neutropenia.  Clarification by the research 
coordinator would have been helpful to understand if the patient was reporting neutropenia or 
delayed wound healing because the patient was experiencing symptoms stemming from these 
side effects (e.g. fever related to neutropenia, or pain related to delayed wound healing).  
The TRSC demonstrated good reliability in this study.  Desired values for Cronbach’s 
alpha are 0.70 or higher in an instrument’s early development stages, while a value of at least 
0.80 is appropriate for instruments in later stages of development (Ferketich, 1990).  Cronbach’s 
alpha for the original 25-item TRSC was 0.83, and 0.81 with the added symptoms, indicating 
good reliability/internal consistency.  This is consistent with other studies using the TRSC, that 
reported Cronbach’s alpha from 0.70 to 0.83 (Gonzalez et al., 2011; Piamjariyakul et al., 2010; 
Williams et al., 2001; Williams et al., 2006a; 2006b; Williams et al., 2010a; 2010b; Williams et 
al., 2011; Williams et al., 2013; Williams et al., 2015a).  
Health-Related Quality of Life  
Health-Related Quality of Life – Linear Analogue Self Assessment (HRQOL-LASA) 
scores.  As a whole, the sample reported relatively high HRQOL with a combined mean 
HRQOL-LASA score of 46.8 (SD = 8.4).  In a study by Sreedhar (2016), mean HRQOL-LASA 
scores for patients undergoing chemotherapy and/or radiation therapy were lower (M = 44.2) 
compared to this study.  Other studies using instruments to measure HRQOL other than the 
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HRQOL-LASA have shown that HRQOL levels among cancer patients are similar to healthy 
controls (DeBoer et al., 2000; Ganz et al., 2004; Hammerlid & Taft, 2001; Rudberg et al., 2002).  
Results from this study suggest that despite a life-threatening illness and pervasive symptoms, 
cancer patients maintain a reasonably high HRQOL.  
This study found that the average total HRQOL-LASA score was higher for patients 
receiving matched therapy (M = 48.1, SD = 7.5) than the average total HRQOL-LASA score for 
patients receiving not matched therapy (M = 45.4, SD = 9.1).  Patients receiving matched therapy 
had lower mean TRSC scores in this study, therefore it was not surprising to see that they also 
had higher HRQOL-LASA scores.  This is consistent with prior studies showing that patients 
who reported lower TRSC scores also reported higher HRQOL-LASA scores (Gonzalez et al., 
2011; Heinze, 2012; Williams et al., 2013; Williams et al., 2011).  Since patients receiving 
matched therapy also had a higher number of prior lines of therapy, results may have been 
related to an increased efficacy in symptom management over time and thus improvement in 
HRQOL.  
Improvement in cancer patients’ HRQOL over time was not measured in this cross-
sectional study, but is supported in multiple other studies (Burkett & Cleeland, 2007; Hess & 
Stehman, 2012; Huang et al., 2013; Jeffe, Perez, Cole, Liu, & Schootman, 2016; Leung, 
Pachana, & McLaughin, 2014; Taira et al., 2011).  Longitudinal studies have shown that despite 
short-term decreases in QOL during chemotherapy (Ganz et al., 2011; Jeffe, et al, 2016; Taira et 
al., 2011), QOL often improves significantly over time (Burkett & Cleeland, 2007; Hess & 
Stehman, 2012; Huang et al., 2013; Jeffe et al., 2016; Leung et al., 2014).  Many of these studies, 
however, contained a population that was being treated for curative intent, and thus had a finite 
treatment period.  Other longitudinal studies of patients with metastatic disease found that 
patients reported lower HRQOL around the time of diagnosis, but that over time, their HRQOL 
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improved (Anderson, Carpenter, Yang, & Shapiro, 2007; Willis, Lewis, Ng, & Wilson, 2015).  
These findings are consistent with those by Meisel et al. (2012) who showed that women living 
with metastatic breast cancer for greater than five years reported higher overall QOL compared 
to women newly diagnosed with metastatic disease.  These studies may indicate increased coping 
strategies or resiliency, which has been associated with increased HRQOL in other studies 
(Chirico et al., 2017; Filazoglu & Griva, 2008).  In this study, patients receiving matched therapy 
may have had greater coping strategies and thus higher HRQOL.  Although this study did not 
capture the patients’ time since diagnosis, it can be inferred that patients receiving matched 
therapy had been diagnosed for a longer period since there was a higher frequency of stage 4 
disease and a higher number of prior lines of therapy in this group.  Patients who were receiving 
not matched therapy may still be adjusting to the emotional and physical changes that a cancer 
diagnosis brings, thereby reflecting a lower HRQOL-LASA score.    
Another potential reason for higher reports of HRQOL in patients receiving matched 
therapy is that patients gained hope from a novel therapy.  Several qualitative-based studies have 
indicated that hope is an indicator of higher QOL (Luoma & Hakamies-Blomqvist, 2004; 
Sarenmalm, Thoren-Jonsson, Gaston-Johansson, & Ohlen, 2009; Svensson, Brandberg, Einbeigi, 
Hatschek, & Ahlberg, 2009).  Luoma & Hakamies-Blomqvist (2004) found that continuing 
cancer treatment allowed patients to feel comforted and optimistic about their QOL and longer 
survival.  This was consistent with findings by Sarenmalm et al. (2009) who found that women 
with breast cancer associated hope with continuing treatment, and that their biggest fear was 
being told there were no other treatment options.  Many patients who seek matched therapy have 
limited treatment options.  Perhaps by being able to continue to fight their cancer with additional 
therapy, they are more hopeful and thus have higher HRQOL.  The investigator’s clinical 
experience confirms that patients who seek matched therapy are hopeful about the potential of 
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the increased efficacy associated with matched therapy, but there were no existing studies found 
on this topic.  Since patients receiving matched therapy may have been living longer with cancer, 
they may have participated in support programs to help them cope and foster hope, which led to 
increased HRQOL.  Support programs for patients with cancer include strategies to improve 
coping skill that have been shown to increase patient hope levels (Lichwala, 2014).  Other 
studies have reported an association between increased hope and decreased distress (Stanton et 
al., 2000), as well as positive experiences of living with cancer, including personal and spiritual 
growth (Ahmad, Muhammad, & Abdullah, 2011; Chunlestskul, Carlson, Koopmans, & Angen, 
2008; Sarenmalm et al., 2009), having a new perspective on life, and an increased gratitude for 
their own life (Sarenmalm et al., 2009).  
In addition to mean total HRQOL-LASA scores, mean ratings on overall QOL, overall 
mental well-being, overall physical well-being, overall emotional well-being, level of social 
activity, and overall spiritual well-being were higher for patients receiving matched therapy than 
for patients receiving not matched therapy.  That the mean score for, “level of social activity” 
was more than one point higher for patients receiving matched therapy compared to the mean 
score for patients receiving not matched therapy was surprising in a group where the majority of 
patients had advanced disease.  It could be that patients with advanced disease are more 
intentional with their social activities or attempt to enrich their relationships (Burkett & 
Cleeland, 2007).  Svensson and colleagues (2009) found that certain actions such as seeking 
social support positively impacted HRQOL, and served as an important coping mechanism.  
Leung and colleagues (2014) found social support to be an important influence on HRQOL, 
which is consistent with other studies (Park, Bae, Jung, & Kim, 2012; So et al., 2012).  It should 
be noted that most of these studies were conducted in the breast cancer population; data on 
HRQOL in gynecologic patients are sparse and mostly related to surgical outcomes.       
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Cronbach’s alpha for the HRQOL-LASA was 0.89, thereby indicating good 
reliability/internal consistency.  Results align with prior studies using the HRQOL-LASA, that 
reported Cronbach’s alpha from 0.83 to 0.93 (Heinze, 2012; Locke et al., 2007).       
Multiple Linear Regression 
Associations between type of therapy and symptom occurrence and severity.  In this 
study, therapy type (matched or not matched therapy) was not significantly associated with 
symptom occurrence and severity (total TRSC score) and only explained 1% of the variance in 
symptom occurrence and severity when entered into the regression model alone.  Although this 
study did not find a significant association between therapy type and symptom occurrence and 
severity, the findings have important clinical implications.  This study is the first of its kind to 
demonstrate that, in this sample, symptom occurrence and severity was not any worse for 
patients receiving matched therapy.  Indeed, mean TRSC scores were lower for patients 
receiving matched therapy.  The implementation of matched therapy is a new concept in routine 
oncology practice, and based on the investigator’s clinical experience, many clinicians are fearful 
of the potential side effects caused by novel drug combinations.  Although not specific to 
matched therapy, this concern was articulated by Dy and Adjei (2013) who cited frequent and 
severe toxicities associated with targeted therapies.  They argued that the toxicities were no less 
severe, just different compared to chemotherapy.  It should be noted that the toxicities discussed 
by Dy and Adjei (2013) were determined by a clinician and not self-reported by the patient.  
Understandably, oncology clinicians might be uneasy with implementing matched therapy since 
it has not been examined in traditional clinical research phased studies (NCI, 2016b) prior to 
clinical use.  However, the average amount of time elapsed during the phased study process is 
approximately 14 years (ACS, 2016).  With the rapid increase of knowledge about cancer 
biology being gained by genomics, and with the potential promise of improved outcomes with 
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matched therapy, waiting 14 years is no longer acceptable for many patients or clinicians 
(DeVita et al., 2014; Mukherjee, 2016).  This has led to a larger, societal-wide discussion of 
using matched therapy in cancer care (Gladwell, 2015; Mukherjee, 2016).  Many patients, 
clinicians, and scientists believe that while protecting patients is vital, there is also an inordinate 
amount of over-regulation that occurs in both drug development and in conducting clinical trials 
that ultimately prevents patients accessing the drugs they need (DeVita et al., 2014).  
Furthermore, traditional cancer clinical trials are meant to find statistical significance between 
groups of heterogeneous patients, yet with the movement toward personalized medicine the 
groups will be inherently smaller (DeVita et al., 2014).  This is important to recognize when 
examining statistical significance of symptoms in cancer trials since adequate power to achieve 
statistical significance may not be attainable in single-studies.  Meta-analyses of smaller, single 
studies may be needed to address this issue.  Also, in the context of matched therapy or other 
personalized medicine initiatives, descriptive statistics can offer important clinical information 
for the patient and clinicians. 
The only variable significantly associated with symptom occurrence and severity in this 
study was the timing of the prior line of therapy.  Patients who had prior therapy less than three 
months before the onset of the current therapy type had significantly higher TRSC scores 
compared to patients who had no prior therapy.  Surprisingly, data to support the relationship 
between the timing of the prior line of therapy and symptom occurrence and severity are lacking.  
Boland et al., (2013) characterized symptom burden in a sample of patients with multiple 
myeloma and assessed the median number of years since diagnosis as well as number of lines of 
prior therapies, but did not include the timing of the prior line of therapy.  Likewise, Lewis et al. 
(2015) and Kirkova et al. (2011) examined multiple factors influencing the symptom prevalence 
of cancer patients, including the number of years since diagnosis and if they had received prior 
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therapy, but the timing of the prior line of therapy was not included in the model.  Janz and 
colleagues (2007) did collect data regarding the time interval from initial surgical treatment for 
breast cancer to the time of questionnaire completion (symptom experience and QOL measures), 
yet the researchers did not control for this variable in the regression model.  The results of this 
study suggest that the timing of the prior line of therapy is an important factor to examine in 
future studies regarding the symptom experience of cancer patients.  
The person and health/illness variables originally chosen for this study (age, cancer type 
and stage, length of current therapy, number of prior lines of therapy, number of comorbidities) 
for inclusion in the multiple linear regression were also not significantly associated with TRSC 
total scores.  This conflicts with other studies showing significant associations between higher 
symptom burdens and younger age (Cataldo et al., 2013; Kirkova et al., 2012), higher symptom 
burdens and higher stages of disease (Kirkova et al., 2011; Walsh et al., 2000), higher symptom 
burdens and longer length of therapy (Spichiger et al., 2011), higher symptom burdens and a 
higher number of prior lines of therapy (Lewis et al., 2015), and higher symptom burdens and a 
greater number of comorbidities (Hamaker et al., 2014; Shayne et al., 2006; & Van Cleave et al., 
2013).  Concerning stage of cancer however, findings are consistent with those by Valeberg and 
Grov (2013) who found no significant association between symptoms and stage of cancer.  For 
this study, results may be because there were differences between how gynecologic and breast 
cancers were documented in the EHR in terms of stage.  Patients with gynecologic cancers were 
staged at diagnosis (usually at the time of surgery) and that stage did not change even if the 
disease later became metastatic.  For example, a patient who was diagnosed with stage 3 disease 
and whose cancer later metastasized was still referred to as having stage 3 disease.  Patients with 
breast cancer, however, were staged according to their current state.  Thus, a patient with breast 
cancer diagnosed with stage 3 disease, whose cancer later metastasized, was classified as stage 4.  
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Still, the overall model explained only 10% of the variance in symptom occurrence and severity, 
suggesting that the symptom experience is a complex and multifactorial process, and there were 
other factors that influenced the symptom experience not accounted for in this study.   
 Potentially, the side effect profile of each individual therapy/drug was an influential 
factor on TRSC total scores.  Patients receiving not matched therapy were generally receiving 
chemotherapy only, while patients on matched therapy were receiving a combination of 
chemotherapy and targeted therapy or targeted therapy alone.  Each drug class has certain side 
effects, some of which are unique and some of which overlap with other drug classes.  
Descriptive data regarding the type of concurrent therapy were collected, but were not included 
in the linear regression models.  This would have been difficult to execute since the drug 
combinations were vast and the study would have been under-powered to account for every 
possible combination.       
 Other person factors not accounted for that may also have influenced symptom 
occurrence and severity include socioeconomic status (SES), education levels, and symptom 
management interventions.  The type of insurance and type of drug coverage were collected for 
the descriptive aspect of this study, but were not included in the linear regression models.  
Income levels were not collected in this study, however, past studies have found that lower 
income levels were predictive of an increased number of symptoms in cancer patients (Ashing-
Giwa & Lim, 2011; Barton-Burke, Smith, Frian, & Loggins, 2010; Bickell & Cohen, 2008; 
Eversley et al., 2005; Vona-Davis, & Rose, 2009).  Education levels may also influence a 
patient’s ability to self-manage symptoms, although there is surprisingly little research found on 
this topic.  A study by Herdon, Kornblith, Holland, and Paskett (2008) revealed that a lower 
education level was significantly associated with poorer outcomes (e.g. survival) in a secondary 
analysis of 1,577 patients with lung cancer.  The authors also found that lower levels of 
111 
 
education were significantly associated with poorer performance status, which may be due to 
symptoms, however symptoms were not reported in the study (Herdon et al., 2008).  In contrast, 
the study by Leach and colleagues (2015) did not find education to significantly influence 
chronic symptoms and comorbidities in a sample (N=1527) of long-term cancer survivors, 
including patients with a history of breast and gynecologic cancers.  However, education level 
may have an impact on the patient’s sense of self-advocacy, since patients with higher education 
levels may be more resourceful and seek out additional information and/or support.  A 
qualitative study by Smith, Dixon, Trevena, Nutbeam, and McCaffery (2009) revealed that 
compared to patients with higher education levels, patients with lower education levels were less 
involved in decision making related to their own health care needs and generally relied on the 
provider to tell them what to do.  Future studies should explore additional person factors and 
their influence on symptom occurrence and severity.  
This study also did not collect data on nor control for types of interventions for symptom 
amelioration, which can influence symptom occurrence and severity.  A variety of interventions 
are typically prescribed and suggested for patients that are receiving cancer therapy.  For 
example, medications to control nausea, pain, sore mouth, numbness in fingers and/or toes, etc. 
are often prescribed.  Other non-medication interventions typically suggested are massage, 
exercise, acupuncture, and dietary changes.  Multiple prior studies using the TRSC also used a 
companion self-report tool called the Self Care Method (SCM) form (Williams et al., 2010a; 
2010b; Williams et al., 2015; Williams et al., 2006a; Piamjariyakul et al., 2010).  The SCM form 
is based on the TRSC so that if symptoms are reported, the patient is asked to also report what 
self-care method(s) they used to control the symptoms and if the intervention was helpful 
(Piamjariyakul et al., 2010).  As previously mentioned, patients receiving matched therapy had a 
higher number of prior lines of therapy and therefore may have implemented previously 
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developed strategies to alleviate symptom occurrence and/or severity.  Perhaps by using the 
SCM in tandem with the TRSC with future studies, categories could be created based on the type 
of intervention used for the symptom(s) and included in the regression model to examine 
potential associations between type of intervention and symptom occurrence and severity.  This 
study would have been under powered with the addition of this variable, but could be considered 
for future research.  Overall, findings from this study provide initial evidence that the 
implementation of matched therapy showed little change in to the patients’ symptom experience.      
 Associations between type of therapy and health-related quality of life.  This study 
found that therapy type (matched versus not matched) was not significantly associated with 
HRQOL (total HRQOL-LASA score), and alone, only explained 3% of the variance in HRQOL-
LASA scores.  This is the first known study examining the associations between therapy type 
(matched or not matched) and HRQOL in a sample of breast and gynecologic cancer.  As 
previously discussed, this is clinically important since there is no prior data documenting the 
impact on patients who are receiving matched therapy.  Understanding the impact of new cancer 
therapies and treatment modalities on patients not only in terms of survival but also on patient 
reported outcomes like HRQOL is crucial to patients and clinicians in order to have meaningful 
discussions about specific therapy-related risks and benefits (Bottomley et al., 2005; McFarland, 
2014; Osaba, 2011).  Findings from this study showed that HRQOL was no worse when 
receiving matched therapy, and that even though it was not statistically significant, that the mean 
total HRQOL-LASA score was higher for patients receiving matched therapy.   
The added person and health/illness variables of age, cancer type and stage, length of 
current therapy, timing of prior lines of therapy, number of prior lines of therapy, and 
comorbidities to the model explained 11% of the variance in HRQOL, which falls within the 9% 
to 27% variance in HRQOL found by Janz et al. (2007) for person factors (sociodemographic) 
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and health/illness factors (prior health status, clinical, and diagnosis factors) among breast cancer 
patients.  On its own, age was not found to be significantly associated with HRQOL, which 
confirms findings from Gotze, Ernst, Brahler, Romer, and von Klitzing (2015) but differs from 
findings by Mkanta, Chumbler, Richardson, and Kobb (2007), who found that older patients 
consistently reported better HRQOL compared to their younger counterparts.  The average age of 
the patients in the Mkanta et al. (2007) study was higher (M = 63.7) compared to the average age 
of patients in this study (M = 56) however, and the sample size was small (N = 48).  Cancer stage 
was also not significantly associated with HRQOL in this study, which contrasts with findings 
from other studies (Ferreira et al., 2008; Gotze et al., 2015).  Ferreira et al. (2008) for instance 
found that the presence of metastases was associated with lower HRQOL scores in the physical 
domain, while Gotze et al. (2015) found that patients with cancer stages from 0 – 2 had higher 
HRQOL scores in the mental domain compared to patients with cancer stages from 3 – 4.  As 
discussed in the previous section, the differences between how the gynecologic and breast 
cancers were documented in the EHR in terms of stage is acknowledged, which may have 
implications for identifying a significant relationship between stage and HRQOL.   
Cancer type was not associated with HRQOL in this study.  This confirms findings from 
Popovic et al (2013) who examined predictors of QOL among a sample of cancer patients across 
17 total studies using weighted linear regression analysis.  However, only three of the 17 studies 
contained a sample of cancer patients with heterogeneous diagnoses; the majority of the studies 
in the analysis were patients with the same diagnosis.  The number of comorbidities was also not 
associated with HRQOL in this study.  Results are in contrast to those from Wu and Harden 
(2015) who found that patients with an increased number of comorbidities had significantly 
poorer QOL.  However, patients in this study had a higher symptom burden, thus it is unclear if 
the higher number of comorbidities or the higher symptom burden was associated with poorer 
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QOL.  It should be noted that the aforementioned comparison studies used HRQOL instruments 
other than the HRQOL-LASA in their analysis, which does not allow for direct comparisons 
given the potential differences in the underlying health dimensions assessed. 
In this study, higher number of prior lines of therapy was associated with a higher 
HRQOL.  This was an unexpected finding, but could be reflective of the difference in HRQOL 
between patients who are newly diagnosed and patients who have been diagnosed with cancer 
for a longer period as previously discussed for TRSC scores.  This conflicts with findings by 
Gotze and colleagues (2015) who found that patients who had been diagnosed with cancer for a 
longer period had lower physical and mental HRQOL scores.  Brothers and Andersen (2009) 
found that for women who were newly diagnosed with breast cancer, feelings of hopelessness 
and difficulties in adjusting to their diagnosis were common.  Other studies have shown that 
HRQOL in women with metastatic breast cancer improves over time (Andersen et al., 2007; Oh 
et al., 2004; Meisel et al., 2012).  Longitudinal improvements in self-care and self-symptom 
management and effect on HRQOL was not measured in this cross-sectional study. 
The addition of symptom occurrence and severity (measured by the total TRSC score) to 
the model explained 20% of the total variance in HRQOL.  The analysis showed that symptom 
occurrence and severity was significantly associated with HRQOL after controlling for all other 
variables in the model.  These findings were confirmed by Janz et al. (2007) who found that 
symptom burden accounted for 18% to 60% of the variance in QOL outcomes in a sample of 
breast cancer patients.  However, patients in this study had recently completed or stopped cancer 
therapy, and were not currently on therapy while the symptom assessments were taken.  Like this 
study, Gonzalez et al. (2011) used the same symptom and HRQOL instruments (TRSC, 
HRQOL-LASA), and found that higher symptom scores were significantly associated with lower 
HRQOL scores.  Other studies have also found that a higher symptom burden from cancer and/or 
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cancer therapies is significantly associated with poorer HRQOL (Ferreira et al., 2008; Gonzalez 
et al., 2011; Huang et al., 2013; Hyland & Sodergren, 1996; Miaskowski et al., 2006; Montazeri, 
2008; Sloan, Cella, & Hays, 2005; Smith et al., 2013; Williams et al., 2013; Williams et al., 
2011).  In contrast, a number of other studies have shown that despite persistent cancer therapy- 
related symptoms, HRQOL isn’t always impacted (DeBoer et al., 2000; Ganz et al., 2004; 
Hammerlid & Taft, 2001; Rudberg, Carlsson, Milsson, & Wikblad, 2005).  However, these 
studies were conducted in samples of patients who had completed their cancer therapy, and with 
different symptom and HRQOL measures. 
Study results suggest that symptom occurrence and severity significantly influences 
HRQOL among patients receiving matched therapy and not matched therapy, and that symptoms 
and HRQOL are separate concepts that are influenced by multiple factors.  Assessments of 
HRQOL in cancer care have greatly increased over the years, but patients and clinicians also 
desire concrete information about what symptoms to anticipate with new therapies.  Neither 
HRQOL nor symptom occurrence and severity can serve as proxies for one another.  For novel 
cancer therapies like matched therapy, it will be important to collect data on the symptoms 
experienced as well as HRQOL.         
Study Limitations 
There are a number of limitations to this study.  The retrospective, correlational design in 
addition to the cross-sectional nature of the data limits the study to assessment of association not 
causation (Shadish et al., 2002).  The patients’ symptoms (TRSC score) and HRQOL (HRQOL-
LASA scores) were unknown at baseline, prior to starting the matched or not matched therapy.  
Therefore, potentially significant differences in symptoms and HRQOL between patients 
receiving matched versus not matched therapy at baseline may have existed.  After completing 
the TRSC and HRQOL-LASA measures, patients may have had more difficulty in tolerating 
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their therapy, which was not captured in this study by repeat measurement of symptoms and 
HRQOL.  In addition, data on the characteristics of patients who did not complete the TRSC and 
HRQOL during treatment was not collected, thus unknown, thereby possibly decreasing the 
generalizability of the study.  Other limitations to generalizability include the homogenous ethnic 
and the female-only sample.  Differences in symptom occurrence and severity as well as 
HRQOL may exist among different ethnic groups, between genders, or among patients with 
different types of cancer and future studies should consider a more diverse population.   
Another limitation is that the type of concurrent therapy may have influenced TRSC and 
HRQOL-LASA scores, which was not measured in this study.  Likewise, the type of prior lines 
of therapy were not included in the regression analysis.  Although different therapies and/or 
treatment modalities can cause different symptoms, accounting for each different combination is 
probably not feasible for the analysis.  However, collapsing the concurrent and/or prior line of 
therapy drugs into classes (e.g. chemotherapy only, targeted therapy only, combination 
chemotherapy/targeted therapy) and entering these into the linear regression model could be 
considered in future studies.  It should be noted that the operational definition of the variable, 
“prior lines of therapy” in this study was different than other research studies and different from 
their quantification in clinical practice.  For example, the treatment plan for a patient with breast 
cancer receiving neoadjuvant therapy would traditionally be referred to as one line of therapy but 
may include the following: two phases of chemotherapy, surgery, radiation therapy, and 
endocrine therapy.  A different patient with breast cancer may undergo surgery followed by 
radiation therapy, which in traditional terms would also be referred to as one line of therapy.  To 
more appropriately examine the effect of prior therapy on symptom occurrence and severity for 
this study, the decision was made to count each phase as a line of therapy due to the nature of 
therapy-related symptoms compounding one another.  Therefore in the former example, the 
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number of lines of therapies would be recorded as five, and the latter example would be counted 
as two.  This may have limited the comparison of results between studies.  Moreover, prior 
studies examining outcomes of matched therapy have classified patients receiving endocrine 
therapy and/or trastuzumab as receiving matched therapy since the therapies are “matched” to 
the tumor’s ER/PR and HER2 status respectively regardless of their genomic profiling results.  
In this study, endocrine and/or trastuzumab therapy that was not chosen based on genomic 
profiling results was considered not matched, thereby potentially limiting the ability to detect 
differences between groups and the ability to compare to other studies.  Lastly, patients in this 
study rated their HRQOL relatively high overall which may have limited the ability to detect an 
association between therapy type and HRQOL. 
Implications for Study Conceptual Framework 
The conceptual framework used for this study was the SMT (Dodd et al., 2001) and 
research questions focused on the symptom experience as measured by the TRSC and the 
outcome of quality of life as measured by the HRQOL-LASA.  Person (age, ethnicity) and 
health/illness (cancer therapy type, cancer type and stage, comorbidities, number of prior lines of 
therapy, timing of prior line of therapy, and length of therapy) variables were identified from the 
SMT for inclusion in this study.  Results from this research study provided support for the 
relationship between health/illness factors and the symptom experience and can serve as a 
hypothesis-generating study to advance symptom and HRQOL-related knowledge in 
contemporary cancer care.  Specifically, this study found a significant relationship between the 
timing of the prior line of cancer therapy and the symptom experience.  That is, patients who had 
received a prior line of cancer therapy within three months of the current therapy had 
significantly higher symptom occurrence and severity scores compared to patients with no prior 
therapy.  Consistent with the SMT, this study also found a relationship between the symptom 
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experience and the outcome of QOL.  Specifically, lower symptom occurrence and severity was 
associated with higher HRQOL.  Interestingly the health/illness variable—number of prior lines 
of therapy—was significantly associated with HRQOL, indicating that perhaps components 
within the “symptom management strategies” concept may directly or indirectly influence 
HRQOL, which were not measured in this study.  Future research should re-examine the link 
between the health/illness factor—therapy type (matched or not matched therapy)—and the 
patient symptom experience as well as HRQOL using a larger number of patients.  Additionally, 
future research should examine the link between the components of symptom management 
strategies and the symptom experience and HRQOL for patients receiving matched versus not 
matched therapy.  
Recommendations for Future Research 
This is the first study to examine symptom occurrence and severity and HRQOL in 
cancer patients receiving matched therapy.  Prospective, longitudinally-designed studies are 
needed to adjust for baseline differences and to follow changes in symptoms and HRQOL over 
time.  One way to achieve this is to embed symptom and HRQOL collection within cancer 
treatment clinical trials.  In doing so, results from larger sample sizes can be examined and 
researchers can also investigate the effect symptoms may have on adherence to cancer therapies 
that may ultimately contribute to overall survival.  Most of the studies concerning symptoms and 
HRQOL have been conducted in samples of Caucasian women with breast cancer, therefore 
conducting future studies in a more heterogeneous population will also be important for 
generalizability purposes.  
This study classified patients as receiving matched therapy if their therapy was guided by 
genomic profile results.  Other studies examining the efficacy of matched therapy considered 
therapies targeting hormone receptors (e.g. endocrine therapy) and/or HER2 receptors (e.g. 
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trastuzumab) as matched therapy even if the patients did not undergo genomic profile testing 
(Schwaederle et al., 2015).  Future studies with larger sample sizes could also take into account 
personalized therapies that were chosen for reasons other than genomic testing to assist in the 
ability to detect differences between groups more robust.   
Future research should include the evaluation of the adequacy of symptom assessment 
tools, including the TRSC.  The importance of assessing cancer therapy-related symptoms will 
continue to grow given the rise of targeted therapies, many of which are given orally, 
continuously, and for longer durations.  Symptoms that occur from these therapies may be more 
chronic in nature and thus under-reported by clinicians (Kluetz et al., 2016).  Ongoing qualitative 
and quantitative studies are paramount to elicit relevant and meaningful cancer therapy-related 
symptoms.  The TRSC was developed over 20 years ago and given the change in cancer 
therapies, under-reporting of relevant symptoms may occur.  The potential for the under-
reporting of symptoms is supported by the substantial proportion of the sample that added 
symptoms to the TRSC for this study (n = 37, 29%).  It is important to confirm these findings in 
future studies since multiple other studies using the TRSC found that fewer than 2% of patients 
have added symptoms (Piamjariyakul et al., 2010; Williams et al., 2001; Williams et al., 2006a; 
Williams et al., 2010a; 2010b; 2011; 2013; 2015).  Many of the prior studies using the TRSC 
were conducted outside of the United States, therefore differences in the symptom experience 
and/or differences in the self report of symptoms may exist due to culturally-related factors and 
thus warrant further examination in future studies.  In addition to the large number of added 
symptoms, this study also found that several symptoms on the TRSC were infrequently 
encountered (jaw pain, soreness in vein where chemotherapy was given, fever), suggesting the 
need for future revisions so that relevant and meaningful symptoms are being assessed. 
Validation of the revised TRSC should be completed that includes patients receiving matched 
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therapy.  Also, validation of the psychometric properties of the HRQOL-LASA should be 
performed with patients receiving matched therapy since this instrument has not been previously 
validated in this population.  The Cronbach’s alpha for both measures however showed good 
reliability in this study, and the strong inverse correlation between the measures (B = -0.361, p = 
0.000) found in the regression analysis demonstrated construct validity.  
Historically, most oncology clinical trials have captured only objective therapy-related 
side effects, referred to as adverse events (AEs).  Capturing AEs is a routine part of any clinical 
trial and a standardized assessment called the Common Terminology Criteria for Adverse Events 
(CTCAE) is used.  Assessment of these AEs, however, is done by the clinician, even for 
symptoms like nausea or peripheral neuropathy.  Organizations such as the NCI and FDA have 
advocated for patient reported symptom-assessments since patients are best positioned to report 
their own symptoms (Kluetz, Chingos, Basch, & Mitchell, 2016).  A standardized symptom 
assessment across oncology clinical trials will be important to compare and examine important 
information about tolerability of cancer therapies, leading to meaningful discussions about risk-
benefit with the patient.  Comparing findings across trials may become increasingly necessary 
since future cancer therapy trials involving matched therapy may not be adequately powered due 
to the diverse and substantial number of potential therapy combinations.  The TRSC is an 
efficient instrument for patients and clinicians in a clinical setting, but it’s completeness for 
research purposes requires further investigation.  Studies using the TRSC plus other symptom 
assessment tools should be considered for establishing concurrent validity.  
Future studies should examine potentially important mediator and moderator variables 
given the complexity of and multiple influences on the symptom experience and HRQOL.  One 
variable that is becoming increasingly important in cancer care and that deserves further 
exploration is the financial impact on patients.  Medical debt caused by cancer care is an 
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unfortunate reality (Zafar, 2015) and has been linked to poorer HRQOL (Fenn et al., 2014; Zafa 
et al., 2015), poorer quality of care, and limited access to contemporary cancer care (Zafar, 
2014).  Out-of-pocket costs are exceptionally high for cancer patients, often because the cost of 
their medications require high co-pays.  This may include medications used to defray symptoms, 
which may lead to greater odds of noncompliance (Hershman et al., 2011; Neugut et al., 2011).  
Examining the influences on the symptom experience and HRQOL due to the cost of cancer care 
warrants further research.   
Another variable to consider in future studies includes the time elapsed since diagnosis.  
Prior studies have indicated that patients’ ability to cope with their symptoms and disease 
improves over time (Andersen et al., 2007; Andersen et al., 2015; Oh et al., 2004; Meisel et al., 
2012) and even though there were more patients with stage 4 disease receiving matched therapy, 
the stage of disease for this study may not be a reliable indicator for whether the patients are 
newly diagnosed or have been diagnosed for some time.  Future studies could explore the use of 
the variable “metastatic or not metastatic” versus “cancer stage” since the presence of metastasis 
has been associated with HRQOL in previous studies (Ferreira et al., 2008; Gotze et al., 2015).  
Furthermore, examining hope as a variable and its potential relationship with symptoms and 
HRQOL should be considered in future studies since prior qualitative studies have found hope to 
be an important indicator of QOL (Luoma & Hakamies-Blomqvist, 2004; Sarenmalm et al., 
2009; Svensson et al., 2009).  Other variables to include in future studies are length of current 
therapy, and timing of prior lines of therapy since there are little data examining these variables 
in relation to symptoms and HRQOL.   
     Over the past several decades, there has been an exponential increase in the number of 
cancer studies investigating QOL and HRQOL, but this has seemingly been at the expense of 
symptom studies.  This investigator maintains that symptoms and HRQOL are conceptually 
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different yet equally important aspects to cancer care and both need to be included in future 
trials.  This will necessitate clear hypotheses and guidance by an appropriate conceptual 
framework and/or middle range theory in future studies.  Furthermore, qualitative studies 
regarding the perceptions that oncology clinicians have about implementing matched therapy are 
needed since there were no studies found on this topic and may identify important barriers or 
challenges.  Other qualitative studies are needed to explore the patients’ perceptions about novel 
cancer therapies like matched therapy and symptom occurrence and severity.  Knowing what the 
symptom(s) mean(s) to the patients, how it/they impact the patient, and the type of care the 
patient desires will be invaluable information.  If personalized medicine like matched therapy is 
intended to tailor treatment to the individual, then tailoring the care is also paramount.  
Nursing Implications 
Nursing science is concerned with the human response to illness and health making 
symptoms and HRQOL an important area to study.  The survival benefits of matched therapy are 
currently being investigated, therefore the impact of this therapy on the patient is a timely and 
needed research endeavor.  One of the first questions a cancer patient asks during a discussion of 
any new therapy is how they (the patient) will feel.  Results from this study provide foundational 
evidence of the symptom occurrence and severity and HRQOL in cancer patients receiving 
matched therapy, which will better prepare nurses and other health care professionals to provide 
effective cancer care.  Nurses caring for cancer patients must incorporate the assessment of 
symptom occurrence and severity as well as HRQOL into their care.  It is important that nurses 
stay up-to-date in new knowledge related to cancer care since they play an essential role in 
providing anticipatory guidance on potential therapy-related symptoms and in providing 
education about symptom management.  By staying informed, nurses can help assess the barriers 
to matched therapy or other new treatment modalities, particularly the barriers to obtaining 
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potentially life-extending drugs due to costs and insurance coverage issues.  Advocating for the 
expansion of patient assistance programs and supporting policy-changes at the local and national 
level is necessary to improve the current financial toxicities cancer patients face.  These activities 
are encouraged by the NINR, who emphasizes the important contributions nurses can make in 
addressing health disparities and social determinants of health (NINR, 2016).   Nursing science 
must continue to generate new knowledge related to symptoms and HRQOL in the context of 
state-of-the-art cancer care to improve patients’ well-being.      
Conclusions 
Patients with breast and gynecologic cancer receiving matched or not matched therapy 
experience a variety of symptoms that can impact HRQOL, which was confirmed by this study.  
Patients who were receiving matched therapy reported lower levels of symptom occurrence and 
severity compared to patients receiving not matched therapy.  However, this study found no 
significant association between cancer therapy type (matched, not matched) and symptom 
occurrence and severity while controlling for age, cancer type and stage, length of therapy, 
number of prior lines of therapy, timing of prior line of therapy, and comorbidities.  Patients who 
had received prior therapy within three months of the current therapy had significantly higher 
symptom occurrence and severity compared to patients who had not received prior therapy.  
Further research about factors that influence symptoms, such as symptom management strategies 
for patients who receive matched therapy versus those that receive not matched therapy is 
necessary.  This study found that more patients added symptoms to the TRSC (29%) compared 
to prior studies utilizing the TRSC (2%).  Additional studies are needed to confirm these findings 
and to ensure that symptoms that are meaningful to the patient and clinician are being captured.     
Patients who were receiving matched therapy had higher HRQOL compared to patients 
who were receiving not matched therapy.  There was not a significant association between 
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cancer therapy type (matched, not matched) and HRQOL while controlling for person and 
health/illness variables.  Nonetheless there was a significant association between symptom 
occurrence and severity and HRQOL; an increase in symptoms led to a decrease in HRQOL. 
Patients who had received an increased number of prior lines surprisingly had significantly 
higher HRQOL.  Further research is needed to understand the important linkage between 
symptoms and HRQOL, and what factors may mediate or moderate this relationship.  Finally, 
within the context of matched cancer therapy and its potential for increased efficacy, additional 
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THERAPY-RELATED SYMPTOMS CHECKLIST (TRSC) 
Name: __________________________________  Hospital #________   Date:_______ 
 
PLEASE CHECK THE PROBLEMS YOU HAVE HAD IMMEDIATELY AFTER AND SINCE 
YOUR LAST TREATMENT. PLEASE CIRCLE HOW SEVERE THE PROBLEM WAS 
ACCORDING TO THE FOLLOWING SCALE: 
 
0 = NONE 1 = MILD 2 = MODERATE 3 = SEVERE 4 = VERY SEVERE 
 
Phoebe D. Williams, PhD ©Copyright 1995 University of Kansas Medical Center   
 
CHECK EXAMPLE Degree of Severity (CIRCLE) 
x Pain 
 
0 1 2 3 4 
o Taste Change 0 1 2 3 4 
o Loss of appetite 0 1 2 3 4 
o Nausea 0 1 2 3 4 
o Vomiting 0 1 2 3 4 
o Weight loss 0 1 2 3 4 
o Sore mouth 0 1 2 3 4 
o Cough 0 1 2 3 4 
o Sore throat 0 1 2 3 4 
o Difficulty swallowing 0 1 2 3 4 
o Jaw pain 0 1 2 3 4 
o Shortness of breath 0 1 2 3 4 
o Numbness in fingers and/or toes 0 1 2 3 4 
o Feeling sluggish 0 1 2 3 4 
o Depression 0 1 2 3 4 
o Difficulty concentrating 0 1 2 3 4 
o Fever 0 1 2 3 4 
o Bruising 0 1 2 3 4 
o Bleeding 0 1 2 3 4 
o Hair loss 0 1 2 3 4 
o Skin changes 0 1 2 3 4 
o Soreness in vein where chemotherapy was 
given 
0 1 2 3 4 
o Difficulty sleeping 0 1 2 3 4 
o Pain 0 1 2 3 4 
o Decreased interest in sexual activity 0 1 2 3 4 
o Constipation 0 1 2 3 4 
 Other problems (please list below)      
o ______________________ 0 1 2 3 4 
o ______________________ 0 1 2 3 4 
o ______________________ 0 1 2 3 4 




Health-Related Quality of Life (HRQOL), Linear Analogue Self Assessment (LASA) 
ID #: ___________        Date: __________ 
Directions: Please circle the number (0-10) best reflecting your response to the following that 
describes your feelings during the last week, including today. 
A. How would you describe : 
1. your overall Quality of Life ?  
 0             1            2          3            4          5           6          7          8             9           10 
 As bad as it can be                                                             As good as it can be 
2. your overall mental (intellectual) well-being? 
 0             1            2          3            4          5           6          7          8             9           10 
 As bad as it can be                                                             As good as it can be 
3. your overall physical well-being? 
 0             1            2          3            4          5           6          7          8             9           10 
 As bad as it can be                                                             As good as it can be 
4. your overall emotional well-being? 
 0             1            2          3            4          5           6          7          8             9           10 
 As bad as it can be                                                             As good as it can be 
5. your level of social activity? 
 0             1            2          3            4          5           6          7          8             9           10 
 As bad as it can be                                                             As good as it can be 
6. your overall spiritual well-being? 
 0             1            2          3            4          5           6          7          8             9           10 
 As bad as it can be                                                             As good as it can be 
 
